

CITATION REPORT

List of articles citing

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators

DOI: 10.1161/01.cir.98.9.839
Circulation, 1998, 98, 839-44.

Source: <https://exaly.com/paper-pdf/29498559/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1186	Lovastatin is effective in primary prevention of acute coronary events. 1998 , 2, 101		
1185	NIH-FDA Conference: Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications. Abstracts. 1998 , 14, 187-334		14
1184	Epidemiological Evidence for Inflammation in Cardiovascular Disease. 1999 , 82, 826-831		46
1183	Inflammatory Markers in Men with Angiographically Documented Coronary Heart Disease. 1999 , 45, 1967-1973		114
1182	Improving outcome in acute coronary syndromes - as good as it gets?. 1999 , 20, 1533-7		1
1181	Mathematical treatment of autonomic oscillations. <i>Circulation</i> , 1999 , 100, e63-4	16.7	85
1180	C-Reactive protein, serum amyloid A protein, and coronary events. <i>Circulation</i> , 1999 , 100, e66	16.7	1
1179	Natural statins and stroke risk. <i>Circulation</i> , 1999 , 99, 185-8	16.7	100
1178	Mathematical treatment of autonomic oscillations. <i>Circulation</i> , 1999 , 100, e64	16.7	
1177	Inflammation, the acute phase response and atherosclerosis. 1999 , 37, 495-503		56
1176	Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. <i>Circulation</i> , 1999 , 100, 230-5	16.7	1259
1175	Smoldering arteries? Low-grade inflammation and coronary heart disease. 1999 , 282, 2169-71		25
1174	Cardiac neural changes before vasovagal syncope. <i>Circulation</i> , 1999 , 100, e67	16.7	
1173	Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects. 1999 , 22, A27		
1172	Author's reply. 1999 , 22, A27-A27		78
1171	Beta blockers: are they difficult to use in heart failure patients. 1999 , 22, A27, 438		
1170	[Prevention of coronary heart disease--"evidence-based medicine" of antilipemic therapy]. 1999 , 24, 3-12		2

1169	[Mechanisms of plaque stabilization]. 1999 , 24, 26-31	8
1168	[Therapy with CSE inhibitors--more than lipid lowering?]. 1999 , 24, 42-50	1
1167	Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Cholesterol and Recurrent Events. 1999 , 24, 51-6	18
1166	Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells. 1999 , 94, 322-32	47
1165	Inflammation and lipid-lowering treatment. 1999 , 1, 251-5	1
1164	The role of C-reactive protein in cardiovascular disease risk. 1999 , 1, 99-104	56
1163	Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. 1999 , 84, 595-8, A8	45
1162	Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. 1999 , 84, 1018-22	278
1161	Pro-inflammatory effect of oestrogens. 1999 , 13, 217-219	4
1160	Prevention of mortality from coronary heart disease with pravastatin. 1999 , 53, 405-8	
1159	Effect of statins on C-reactive protein in patients with coronary artery disease. 1999 , 353, 118-9	177
1158	Acute coronary syndromes: biology. 1999 , 353 Suppl 2, S115-9	170
1157	C-Reactive protein, serum amyloid A protein, and coronary events. <i>Circulation</i> , 1999 , 100, e65-6	16.7 12
1156	Mechanisms modifying atherosclerotic disease - from lipids to vascular biology. 1999 , 147 Suppl 1, S3-10	41
1155	Hormone replacement therapy and increased plasma concentration of C-reactive protein. <i>Circulation</i> , 1999 , 100, 713-6	16.7 380
1154	Stable versus unstable atherosclerosis: clinical aspects. 1999 , 138, S421-5	76
1153	Bibliography current world literature. 1999 , 6, 41-58	
1152	Is vasculitis a significant component of atherosclerosis?. 1999 , 11, 3-10	11

1151	Modification of coronary artery disease progression by cholesterol-lowering therapy: the angiographic studies. 1999 , 10, 527-34	10
1150	Low-density lipoprotein-independent effects of statins. 1999 , 10, 543-59	166
1149	Effects of statins on carotid disease and stroke. 1999 , 10, 535-41	5
1148	Inflammation markers and coronary heart disease. 1999 , 10, 435-41	87
1147	Evaluating novel cardiovascular risk factors: can we better predict heart attacks?. 1999 , 130, 933-7	210
1146	Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. 2000 , 133, 111-22	180
1145	Use of "unidentified bright objects" on MRI for diagnosis of neurofibromatosis 1 in children. 2000 , 55, 1067-8	7
1144	Neurologic side effects in neuroleptic-naïve patients treated with haloperidol or risperidone. 2000 , 55, 1069	1
1143	High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy. 2000 , 33, 601-10	67
1142	Debate: When should we intervene in unstable angina - Time for an old look?. 2000 , 1, 15-18	
1141	Are statins anti-inflammatory?. 2000 , 1, 161-165	69
1140	Inhibition of monocyte chemotactic protein-1 synthesis by statins. 2000 , 80, 1095-100	266
1139	Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. 2000 , 20, 1375-83	61
1138	Post-hospitalization management of high-risk coronary patients. 2000 , 85, 13B-20B	116
1137	Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon. 2000 , 85, 50B-60B	90
1136	Role of plaque rupture in acute coronary syndromes. 2000 , 86, 15J-23J	14
1135	Should intensive cholesterol lowering play a role in the management of acute coronary syndromes?. 2000 , 86, 35J-42J; discussion 42J-43J	4
1134	Pleiotropic effects of statins. 2000 , 2, 208-17	121

1133	Global risk assessment for lipid therapy to prevent coronary heart disease. 2000 , 2, 424-32		
1132	Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation. 2000 , 2, 269-73		15
1131	A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. 2000 , 78, 562-8		26
1130	HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?. 2000 , 25, 117-25		22
1129	Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterol-lowering independent actions. 2000 , 23, 353-8		31
1128	Images in cardiology. Saddle pulmonary embolism: diagnosis by spiral computed tomography. 2000 , 84, 10		
1127	Inflammation, insulin resistance, infection, diabetes, and atherosclerosis. 2000 , 6, 272-6		21
1126	HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. 2000 , 54, 790-6		101
1125	Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. <i>Circulation</i> , 2000 , 102, 2100-4	16.7	75
1124	A randomized controlled trial of prednisone in Alzheimer's disease. 2000 , 55, 1067		15
1123	HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. 2000 , 55, 1066-7		8
1122	Smoking: back to the future - again?. 2000 , 21, 1570-1		
1121	Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. <i>Circulation</i> , 2000 , 102, 1917-23	16.7	154
1120	Circulating markers of inflammation for vascular risk prediction: are they ready for prime time. <i>Circulation</i> , 2000 , 101, 1758-9	16.7	72
1119	Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. <i>Circulation</i> , 2000 , 101, 2149-53	16.7	765
1118	Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. <i>Circulation</i> , 2000 , 101, 1785-91	16.7	132
1117	Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. 2000 , 20, 2657-62		189
1116	C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. 2000 , 20, 1047-51		136

1115	Brugada syndrome: an electrocardiographic diagnosis not to be missed. 2000 , 84, 1-2	10
1114	C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. 2000 , 20, 1057-60	183
1113	The influence of treatment of hypercholesterolemic patients with simvastatin on plasma chemotactic activity and adherence of neutrophils. 2000 , 75, 85-90	4
1112	Importance of microembolization and inflammation in atherosclerotic heart disease. 2000 , 140, S90-102	23
1111	Elevated inflammatory parameters are associated with lower platelet density in acute myocardial infarctions with ST-elevation. 2000 , 100, 471-8	33
1110	Pravastatin therapy and the risk of stroke. 2000 , 343, 317-26	268
1109	Management of Dyslipidaemias. 2000 , 7, 83-109	3
1108	Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus. 2000 , 9, 194-201	31
1107	Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. 2000 , 321, 199-204	1106
1106	Chronic infection and coronary artery disease. 2000 , 84, 123-48	39
1105	C-reactive protein, inflammation, and coronary risk. 2000 , 84, 149-61, ix	111
1104	Multiple complex coronary plaques in patients with acute myocardial infarction. 2000 , 343, 915-22	769
1103	HMG-CoA reductase inhibitors in the prevention of stroke. 2000 , 59, 1-6	12
1102	Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. 2000 , 152, 359-66	98
1101	Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm. 2000 , 148, 179-88	43
1100	Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. 2000 , 36, 39-43	112
1099	Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. 2000 , 36, 1774-80	107
1098	Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy. 2000 , 35, 358-62	108

1097	C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. 2000 , 342, 836-43	4551
1096	Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. 2001 , 154, 681-9	307
1095	Diurnal rhythms and hemostatic factors in atrial fibrillation: reply. 2001 , 37, 970-971	1
1094	C-reactive protein and electron beam computed tomography: a perfect match?: reply. 2001 , 37, 972	
1093	C-Reactive protein and electron beam computed tomography: a perfect match?. 2001 , 37, 971-2	
1092	Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. 2001 , 37, 839-46	181
1091	Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. 2001 , 37, 2036-41	154
1090	Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. 2001 , 38, 2006-12	102
1089	The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. 2001 , 345, 1014-21	1046
1088	Mechanisms of acute coronary syndromes and the potential role of statins. 2001 , 2, 9-14	13
1087	Clinical relevance of statins: instituting treatment early in acute coronary syndrome patients. 2001 , 2, 15-9	11
1086	Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)--a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness. 2001 , 141, 342-7	17
1085	Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. 2001 , 1, 105-18	103
1084	Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. 2001 , 77, 247-53	151
1083	Pravastatin reduces myocardial lesions induced by acute inhibition of nitric oxide biosynthesis in normocholesterolemic rats. 2001 , 79, 215-21	15
1082	Chemokines in patients with ischaemic heart disease and the effect of coronary angioplasty. 2001 , 80, 55-60	56
1081	High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. <i>Circulation</i> , 2001 , 103, 1813-8	16.7 1051
1080	C-reactive protein and primary prevention of ischemic heart disease. 2001 , 311, 45-8	10

1079	C-Reactive Protein and secondary prevention of coronary events. 2001 , 311, 49-52	18
1078	Therapeutic implications of inflammation in atherosclerotic cardiovascular disease. 2001 , 71, 2066-74	26
1077	Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. 2001 , 1, 411-20	50
1076	In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. 2001 , 21, 1327-32	182
1075	Plasma N-terminal pro-atrial natriuretic peptide predicts death after premature myocardial infarction, but not as well as radionuclide ejection fraction. A ten-year follow-up study. 2001 , 35, 373-8	3
1074	Prevention of a first myocardial infarction. 2001 , 41, 359-67	3
1073	Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. 2001 , 161, 2474-80	100
1072	High-Sensitivity C-Reactive Protein: A Novel and Promising Marker of Coronary Heart Disease. 2001 , 47, 403-411	394
1071	Proposed Cardiovascular Risk Assessment Algorithm Using High-Sensitivity C-Reactive Protein and Lipid Screening. 2001 , 47, 28-30	151
1070	C-Reactive Protein and Cardiovascular Risk: Has the Time Come for Screening the General Population?. 2001 , 47, 9-10	24
1069	Coronary vascular endothelial function and myocardial ischemia: why should we worry about endothelial dysfunction?. 2001 , 12, 475-84	11
1068	Inflammation and coronary heart disease: an overview. 2001 , 9, 31-5	87
1067	Healthy ageing: addressing acute coronary syndrome?. 2001 , 3 Suppl N, N11-5	1
1066	Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. 2001 , 3, 326-32	41
1065	Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors. 2001 , 11 Suppl 1, 85-95	29
1064	Perspectives on vascular biology and diabetes. 2001 , 49, 100-3	0
1063	Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. 2001 , 32, 280-99	341
1062	Reducing cardiovascular risk in diabetes. Which factors to modify first?. 2001 , 109, 26-30, 33-6	10

1061	Dietary modulation of endothelial function: implications for cardiovascular disease. 2001 , 73, 673-86	264
1060	[Pharmacotherapy after cardiac infarction]. 2001 , 42, 699-712	1
1059	End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?. 2001 , 59, 407-14	272
1058	Transcription factor-kappa B (NF-kappa B) and renal disease. 2001 , 59, 415-24	374
1057	Novel clinical markers of vascular wall inflammation. 2001 , 89, 763-71	592
1056	Interleukin-6 and acute coronary syndrome. 2001 , 24, 701-4	116
1055	C-reactive protein and coronary heart disease: diagnostic and therapeutic implications for primary prevention. 2001 , 1, 153-7	13
1054	Statins as immunosuppressive agents. 2001 , 7, 559-61	14
1053	Beyond the cholesterol profile: monitoring therapeutic effectiveness of statin therapy. 2001 , 8, 528-32	5
1052	Can statins reduce the inflammatory response to cardiopulmonary bypass? A clinical study. 2001 , 16, 232-9	24
1051	Role of novel markers of inflammation in patients with stable coronary heart disease. 2001 , 87, 262-6	86
1050	Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. 2001 , 87, 636-9, A10	139
1049	Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction. 2001 , 87, 771-4, A7	45
1048	Laboratory surrogates for anti-atherosclerotic drug development. 2001 , 87, 21A-26A	49
1047	Pleiotropic effects of statins and their clinical significance. 2001 , 88, 291-3	84
1046	The inflamed plaque: cytokine production and cellular cholesterol balance in the vessel wall. 2001 , 88, 12E-15E	36
1045	C-reactive protein and coronary heart disease in western Turkey. 2001 , 88, 601-7	43
1044	Going from immutable to mutable atherosclerotic plaques. 2001 , 88, 2F-9F	30

1043	Emerging perspectives on lipid management: international approaches and global challenges. 2001 , 88, 876-81		2
1042	What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes?. 2001 , 88, 7J-16J		15
1041	Atherosclerosis and the genetic basis of lipoprotein disease. 2001 , 15, 169-183		2
1040	The lack of cardiovascular risk factor management in patients with critical limb ischaemia. 2001 , 21, 143-6		24
1039	Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines. 2001 , 21, 954-87		2
1038	Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. <i>Circulation</i> , 2001 , 103, 926-33	16.7	833
1037	Markers of myocardial damage and inflammation in unstable coronary artery disease. 2001 , 344, 688-9		3
1036	Inflammatory mechanisms. 2001 , 59, 55-68		8
1035	Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. <i>Circulation</i> , 2001 , 103, 1933-5	16.7	605
1034	Markers of the acute phase response in cardiovascular disease: an update. 2001 , 39, 1054-64		10
1033	Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. <i>Circulation</i> , 2001 , 103, 3062-8	16.7	80
1032	Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. 2001 , 21, 255-61		77
1031	Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial. 2001 , 22, 2135-7		37
1030	Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. 2001 , 86, 4216-22		68
1029	High sensitivity C-reactive protein for predicting cardiovascular disease: an inflammatory hypothesis. 2001 , 22, 349-52		46
1028	The role of risk factors in the development of atherosclerosis. 2001 , 38, 401-40		21
1027	Is visceral adiposity the "enemy within"?. 2001 , 21, 881-3		62
1026	Coronary risk factors: new perspectives. 2001 , 30 Suppl 1, S41-7		11

1025	Treatment of older persons with hypercholesterolemia with and without cardiovascular disease. 2001 , 56, M138-45		20
1024	Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. <i>Circulation</i> , 2001 , 103, 163-82	16.7	289
1023	Statins for stroke: the second story?. <i>Circulation</i> , 2001 , 103, 348-50	16.7	16
1022	Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. 2001 , 21, 1712-9		1066
1021	Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. <i>Circulation</i> , 2001 , 103, 1191-3	16.7	355
1020	C-reactive protein in ischemic stroke: an independent prognostic factor. 2001 , 32, 917-24		320
1019	Extent of coronary atherosclerosis and homocysteine affect endothelial markers. 2001 , 52, 589-96		7
1018	Auto-TIPS. 2001 , 77, 98		
1017	The antiinflammatory effects of statins. 2001 , 345, 1209-10; author reply 1210-1		7
1016	Early statin treatment following acute myocardial infarction and 1-year survival. 2001 , 285, 430-6		380
1015	Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. 2001 , 344, 1959-65		1298
1014	New insights into atherosclerotic plaque rupture. 2001 , 77, 94-8		28
1013	Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. 2002 , 42, 835-45		64
1012	Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. <i>Circulation</i> , 2002 , 105, 691-6	16.7	207
1011	Headache as the initial presentation of Wegener's granulomatosis. 2002 , 61, 571-2		6
1010	Autoantibodies against C1q: view on association between systemic lupus erythematosus disease manifestation and C1q autoantibodies. 2002 , 61, 563-4		13
1009	Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. <i>Circulation</i> , 2002 , 106, 1447-52	16.7	301
1008	Relationships among clinical measures of periodontal disease and their associations with systemic markers. 2002 , 7, 79-89		92

1007	High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment. 2002 , 39, 459-97	44
1006	Pharmacologic therapy of lipid disorders in the elderly. 2002 , 11, 247-56	5
1005	Steroid induced psychosis in systemic lupus erythematosus: a possible role of serum albumin level. 2002 , 61, 562-3	14
1004	Statins: balancing benefits, efficacy and safety. 2002 , 3, 469-77	9
1003	Significance of high C-reactive protein levels in pre-dialysis patients. 2002 , 17, 1105-9	60
1002	Effect of ciprofibrate on C-reactive protein and fibrinogen levels. 2002 , 53, 273-7	45
1001	Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. 2002 , 22, 1452-8	196
1000	Principles from clinical trials relevant to clinical practice: Part I. <i>Circulation</i> , 2002 , 106, 1015-21	16.7 78
999	Plasma concentrations of C-reactive protein and fibrinogen in ischaemic stroke. 2002 , 30, 591-6	13
998	Tumour necrosis factor-alpha, inflammatory biomarkers, and atherogenesis. 2002 , 23, 345-7	17
997	Short-term effects of atorvastatin on C-reactive protein. 2002 , 23, 794-9	60
996	Serum amyloid A; in search of function. 2002 , 9, 276-8	5
995	Is time the overriding factor in thrombolytic therapy?. 2002 , 23, 347-9	
994	Atherogenesis--recent insights into basic mechanisms and their clinical impact. 2002 , 17, 2055-64	30
993	Clinical significance of pleiotropic effects of statins: lipid reduction and beyond. 2002 , 9, 1831-50	49
992	Use of statins and aspirin to reduce risks of cardiovascular disease. 2002 , 7, 77-80	15
991	Systemic inflammation, endothelial dysfunction, dietary fatty acids and micronutrients as risk factors for stroke: a selective review. 2002 , 13, 219-24	15
990	C-reactive protein--to screen or not to screen?. 2002 , 347, 1615-7	106

989	Diabetes and atherothrombotic disease: linked through inflammation?. 2002 , 2, 67-73	4
988	Inflammation and cholesterol. 2002 , 4, A18-A25	1
987	Acute-phase reactants and coronary heart disease. 2002 , 2, 417-28	25
986	The Role of Inflammation in Atherosclerosis. 2002 , 13, 203-216	1
985	Acute phase serum amyloid A, cholesterol metabolism, and cardiovascular disease. 2002 , 21, 291-305	32
984	Early statin therapy for acute coronary syndromes. 2002 , 36, 1749-58	12
983	Safety and efficacy of TNFalpha blockade in relapsing vasculitis. 2002 , 61, 559	69
982	Adhesion molecule expression in the synovial membrane of psoriatic arthritis. 2002 , 61, 569-70	7
981	Synovial T cell proliferation to the Yersinia enterocolitica 19 kDa antigen differentiates yersinia triggered reactive arthritis (ReA) from ReA triggered by other enterobacteria. 2002 , 61, 566-7	2
980	Is hirudin a potential therapeutic agent for arthritis?. 2002 , 61, 561-2	14
979	Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet disease. 2002 , 61, 560-1	46
978	Effect of pravastatin on proteinuria in patients with well-controlled hypertension. 2002 , 40, 67-73	98
977	Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum. <i>Circulation</i> , 2002 , 105, 2583-5	16.7 47
976	Leflunomide and hypertension. 2002 , 61, 567-9	72
975	Extremely high dose pravastatin may suppress amyloidogenesis in a mouse model. 2002 , 61, 572	3
974	Silent thyroiditis associated with etanercept in rheumatoid arthritis. 2002 , 61, 565	13
973	Coronary atherogenic risk factors in women. 2002 , 23, 1738-52	57
972	Comorbidity and cardiovascular risk factors in patients with chronic kidney disease. 2002 , 22, 494-506	13

971	C-reactive protein and prognosis after percutaneous coronary intervention. 2002 , 23, 923-5	13	
970	Statins in the prevention and treatment of Alzheimer disease. 2002 , 16, 131-6	67	
969	High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease. 2002 , 17, 325-31	36	
968	Inflammatory markers and coronary heart disease. 2002 , 13, 383-9	78	
967	Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. 2002 , 40, 611-7	87	
966	Statins and stroke: evidence for cholesterol-independent effects. 2002 , 23, 1908-21	61	
965	Genetic variation at the interleukin-1 locus is a determinant of changes in soluble endothelial factors in patients with acute coronary syndromes. 2002 , 103, 303-10	22	
964	Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents. 2002 , 42, 1187-99	39	
963	Fibrates and coronary heart disease reduction in diabetes. 2002 , 9, 312-322	8	
962	Do atherosclerosis and type 2 diabetes share a common inflammatory basis?. 2002 , 23, 831-4	149	
961	Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. 2002 , 112, 275-80	135	
960	Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen. 2002 , 113, 331-4	28	
959	C-reactive protein, statins, and the primary prevention of atherosclerotic cardiovascular disease. 2002 , 5, 42-6	13	
958	Statins and C-reactive protein: considering a novel marker of cardiovascular risk. 2002 , 5, 200-3	7	
957	ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. <i>Circulation</i> , 2002 , 106, 2055-60	16.7	470
956	Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. 2002 , 40, 49-55	35	
955	The role of chemokines in human cardiovascular pathology: enhanced biological insights. 2002 , 160, 91-102	161	
954	Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease. 2002 , 160, 471-6	49	

953	Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. 2002 , 162, 179-85	91
952	Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. 2002 , 162, 245-51	37
951	ACUTE PHASE SERUM AMYLOID A, CHOLESTEROL METABOLISM, AND CARDIOVASCULAR DISEASE. 2002 , 21, 291-305	19
950	C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. 2002 , 360, 1462-7	99
949	C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. 2002 , 317, 1-15	115
948	Plasma alpha2-HS glycoprotein concentrations in patients with acute myocardial infarction quantified by a modified ELISA. 2002 , 319, 27-34	22
947	A comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the normative aging study. 2002 , 144, 95-100	46
946	High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. 2002 , 144, 449-55	52
945	Association of C-reactive protein with coronary heart disease risk factors in patients with type 2 diabetes mellitus. 2002 , 58, 37-44	42
944	Inflammation in atherosclerosis and acute coronary syndromes. 2002 , 1229, 95-102	1
943	Inflammation and atherosclerosis. <i>Circulation</i> , 2002 , 105, 1135-43	16.7 5212
942	Serum lipids act as inverse acute phase reactants and are falsely low in patients with critical limb ischemia. 2002 , 36, 1005-10	12
941	Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit. 2002 , 77, 1085-92	38
940	Inflamaci3n, hemostasia y enfermedad coronaria. La prote3na C reactiva y el d3mero D como marcadores del proceso de la arteriosclerosis. 2002 , 14, 242-257	
939	Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. 2002 , 165, 361-6	102
938	Les statines en th3raputique cardiovasculaire. 2002 , 18, 1257-1265	
937	Elevated C-reactive protein is associated with an increased intima to media thickness of the common carotid artery. 2002 , 13, 57-63	45
936	Interaction of hemostatic genetics with hormone therapy: new insights to explain arterial thrombosis in postmenopausal women. 2002 , 121, 906-20	38

935	Economical Aspects of High-Sensitivity C-Reactive Protein as Predictor of Coronary Heart Disease. 2002 , 2, 61-68	
934	Acute Coronary Syndrome and Early Statin Therapy: What Is the Evidence?. 2002 , 2, 246-250	
933	Multifocal coronary plaque instability. 2002 , 44, 449-54	15
932	Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. 2002 , 89, 145-9	144
931	Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. 2002 , 89, 216-21	45
930	Systemic T-cell activation in stable angina pectoris. 2002 , 89, 754-6	19
929	Effects of statins on six-month survival and clinical restenosis frequency after coronary stent deployment. 2002 , 90, 299-302	15
928	Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. 2002 , 90, 942-6	31
927	Association of serum albumin and atherosclerosis in chronic hemodialysis patients. 2002 , 40, 721-7	93
926	Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia. 2002 , 16, 382-5	17
925	The role of inflammation and infection in coronary artery disease: a clinical perspective. 2002 , 11, 32-34	9
924	Estrogen, statins, and polyunsaturated fatty acids: similarities in their actions and benefits-is there a common link?. 2002 , 18, 178-88	39
923	Management After Myocardial Infarction. 2002 , 4, 41-54	
922	Lipoprotein changes with statins. 2002 , 4, 14-8	7
921	Statins and inflammatory markers. 2002 , 4, 42-7	17
920	Early use of statins in acute coronary syndromes. 2002 , 4, 289-97	1
919	Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes. 2002 , 2, 396-402	16
918	[Statin and cerebrovascular events]. 2002 , 27, 765-71	1

917	[Acute coronary syndrome--better risk stratification by determination of inflammatory parameters?]. 2002 , 97, 63-9		
916	[C-reactive protein in coronary plaques -- prevalence with acute coronary syndrome]. 2002 , 91, 913-20		2
915	Inflammatory bio-markers and cardiovascular risk prediction. 2002 , 252, 283-94		498
914	Statin therapy improves brachial artery endothelial function in nephrotic syndrome. 2002 , 62, 550-7		41
913	Are early clinical effects of cholesterol lowering mediated through effects on inflammation?. 2002 , 176, 147-50		13
912	Inflammation in atherosclerosis. 2002 , 420, 868-74		6489
911	C-reactive protein and coronary artery disease: influence of obesity, caloric restriction and weight loss. 2002 , 13, 316-321		61
910	Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. 2002 , 25, 461-6		28
909	HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. 2002 , 16, 121-6		38
908	Antiinflammatory and immunomodulatory properties of statins. 2002 , 25, 271-85		54
907	The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in patients with unstable angina and non-Q-wave myocardial infarction. <i>Molecular and Cellular Biochemistry</i> , 2003 , 246, 45-50	4.2	22
906	Reduction of infarct size by short-term pretreatment with atorvastatin. 2003 , 17, 25-30		33
905	Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. 2003 , 8, 71-86		112
904	Comparing HMG-CoA reductase inhibitors. 2003 , 26, 115-20		14
903	Connecting the role of C-reactive protein and statins in cardiovascular disease. 2003 , 26, 1139-44		39
902	Inflammation and infections as risk factors for ischemic stroke. 2003 , 34, 2518-32		379
901	C-reactive protein and risk of cardiovascular disease: evidence and clinical application. 2003 , 5, 341-9		80
900	Are cholesterol-lowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor?. 2003 , 5, 38-43		5

899	Early use of statins in acute coronary syndromes. 2003 , 5, 44-51	10
898	C-reactive protein: the pawn has been promoted to queen. 2003 , 5, 101-5	25
897	Are cholesterol-lowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor?. 2003 , 3, 21-6	4
896	HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9. 2003 , 98, 353-61	16
895	[Diabetes and lipids]. 2003 , 153, 469-73	
894	C-Reactive Protein and Cardiovascular Diseases. 2003 , 12, 1-12	17
893	C-reaktives Protein in der Risikovorhersage und Intervention bei kardiovaskulären Erkrankungen. 2003 , 27, 100-112	
892	Usefulness of lowering low-density lipoprotein cholesterol to . 2003 , 92, 1224-7	15
891	Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. 2003 , 92, 1287-93	90
890	Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. 2003 , 92, 1414-8	107
889	Impact of high-sensitivity C-reactive protein on predicting long-term mortality of acute myocardial infarction. 2003 , 91, 931-5	52
888	Association between inflammatory markers, hemostatic, and lipid factors in postinfarction patients. 2003 , 91, 1120-3	20
887	Utility of inflammatory markers in the management of coronary artery disease. 2003 , 92, 10i-8i	64
886	A practical approach to risk assessment to prevent coronary artery disease and its complications. 2003 , 92, 19i-26i	62
885	Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction. 2003 , 92, 298-301	51
884	Usefulness of aortic valve calcium scores by electron beam computed tomography as a marker for aortic stenosis. 2003 , 92, 349-53	50
883	High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. 2003 , 92, 17K-22K	174
882	Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. 2003 , 92, 843-5	48

881	Detecting vulnerable plaque using peripheral blood: inflammatory and cellular markers. 2003 , 16, 231-42	30
880	Anti-inflammatory and immunomodulatory effects of statins. 2003 , 63, 12-23	229
879	Oral health status, C-reactive protein and mortality--a 10 year follow-up study. 2003 , 20, 32-40	75
878	C-reactive protein concentration and concentrations of blood vitamins, carotenoids, and selenium among United States adults. 2003 , 57, 1157-63	111
877	C-reactive protein, inflammation, and coronary risk. 2003 , 21, 315-25	141
876	Chronic infection and coronary artery disease. 2003 , 21, 333-62	52
875	Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia. 2003 , 166, 197-8	8
874	Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. 2003 , 166, 129-35	132
873	Circulating markers of inflammation and atherosclerosis. 2003 , 169, 203-14	314
872	Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. 2003 , 169, 155-8	73
871	Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. 2003 , 169, 283-91	75
870	C-reactive protein and other inflammatory risk markers in acute coronary syndromes. 2003 , 41, 37S-42S	255
869	Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. 2003 , 41, 916-24	187
868	Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. 2003 , 41, 1460-7	94
867	The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. 2003 , 42, 211-6	180
866	C-Reactive protein and cardiac allograft vasculopathy. is inflammation the critical link?. 2003 , 42, 483-5	19
865	Relation of inflammation and benefit of statins after percutaneous coronary interventions. <i>Circulation</i> , 2003 , 107, 1750-6	16.7 166
864	Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment. 2003 , 146, E21	20

863	Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. 2003 , 114, 485-94		40
862	Restenosis after coronary intervention: narrowing C-reactive protein's prognostic potential?. 2003 , 115, 147-9		4
861	C-reactive protein activates complement in infarcted human myocardium. 2003 , 163, 269-75		81
860	Clinical application of C-reactive protein for cardiovascular disease detection and prevention. <i>Circulation</i> , 2003 , 107, 363-9	16.7	1772
859	C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. <i>Circulation</i> , 2003 , 107, 391-7	16.7	1881
858	Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. <i>Circulation</i> , 2003 , 107, 499-511	16.7	4541
857	The PROSPER trial. 2003 , 361, 427		1
856	Statins inhibit high glucose-mediated neutrophil-endothelial cell adhesion through decreasing surface expression of endothelial adhesion molecules by stimulating production of endothelial nitric oxide. 2003 , 65, 118-24		36
855	Development of a point-of-care assay system for high-sensitivity C-reactive protein in whole blood. 2003 , 332, 51-9		77
854	Effects of fluvastatin on plasma levels of low-density lipoprotein subfractions, oxidized low-density lipoprotein, and soluble adhesion molecules: a twenty-four-week, open-label, dose-increasing study. 2003 , 64, 236-47		5
853	Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia. 2003 , 25, 904-18		15
852	Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway. 2003 , 60, 634-9		12
851	Can the premises of the altered homeostatic theory permit improvement in the prevention of ischemic heart disease?. 2003 , 60, 12-25		3
850	Plaque rupture and consequent thromboses probably do not cause acute coronary syndromes. 2003 , 60, 26-35		5
849	The effect of statin therapy on ventricular late potentials in acute myocardial infarction. 2003 , 90, 63-72		37
848	C-reactive protein and coronary events following percutaneous coronary angioplasty. 2003 , 115, 85-90		41
847	Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. 2003 , 145, 248-53		67
846	The prognostic value of high-sensitive C-reactive protein and cardiac troponin T in young and middle-aged patients with chest pain without ECG changes. 2003 , 14, 310-314		5

845	Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. <i>Circulation</i> , 2003 , 108, 2292-7	16.7	355
844	Statin effects beyond lipid lowering--are they clinically relevant?. 2003 , 24, 225-48		360
843	Dietary lipids in the aetiology of Alzheimer's disease: implications for therapy. 2003 , 20, 399-418		26
842	The Multicentre Atorvastatin Plaque Stabilisation (MAPS) Study. 2003 , 10, 11-18		
841	Atorvastatin affects C-reactive protein levels in patients with coronary artery disease. 2003 , 19, 187-91		9
840	C reactive protein for risk stratification in acute coronary syndromes? Verdict: unproven. 2003 , 89, 1288-90		8
839	Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. <i>Circulation</i> , 2003 , 107, 258-63	16.7	44
838	Noncholesterol-lowering effects of statins. 2003 , 37, 301-13		18
837	Macrophage cholesterol efflux and the active domains of serum amyloid A 2.1. 2003 , 44, 2257-69		38
836	Intravascular ultrasound assessment of ulcerated ruptured plaques: a comparison of culprit and nonculprit lesions of patients with acute coronary syndromes and lesions in patients without acute coronary syndromes. <i>Circulation</i> , 2003 , 108, 2473-8	16.7	196
835	Review: Lipid lowering drugs, inflammation and cardiovascular disease. 2003 , 3, 178-182		2
834	Diabetes and Vascular Disease. 2003 , 7, 295-310		
833	Unusual morphologic changes in apical hypertrophic cardiomyopathy. 2003 , 89, 1290		2
832	HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?. 2003 , 10, 169-79		26
831	Monocyte chemoattractant protein-1 and CC-chemokine receptor-2 in severe hypercholesterolaemia. 2003 , 63, 513-9		4
830	High sensitivity C-reactive protein in clinical practice. 2003 , 1, 207-11		23
829	Interleukins in atherosclerosis: molecular pathways and therapeutic potential. 2003 , 55, 133-66		170
828	Inflammatory and thrombotic mechanisms in coronary atherosclerosis. 2003 , 89, 993-7		101

827	Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. <i>Circulation</i> , 2003 , 108, 1368-74	16.7	142
826	Statins and Autoimmunity. 2003 , 1, 97-106		
825	Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. 2003 , 49, 1258-71		165
824	C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. 2003 , 34, 2463-8		144
823	C-reaktives Protein in der Risikovorhersage und Intervention bei kardiovaskulären Erkrankungen/C-Reactive Protein for Risk Prediction and Intervention in Cardiovascular Disease. 2003 , 27, 100-112		
822	Editorial comment--C-reactive protein and vascular risk in stroke patients: potential use for the future. 2003 , 34, 2468-70		3
821	Pathophysiology of atherosclerotic plaque development and rupture: an overview. 2003 , 3, 347-54		14
820	Inflammatory cytokines and cardiovascular disease. 2003 , 2, 257-65		112
819	Platelet activation, inflammatory mediators and hypercholesterolemia. 2003 , 1, 157-69		57
818	C-reactive protein: a novel marker of cardiovascular risk. 2003 , 11, 169-79		43
817	Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. 2003 , 21, 1841-6		106
816	Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. 2003 , 18, 471-8		68
815	. 2003 , 10, 169-179		49
814	Inflammatory biomarkers of the patient with myocardial insufficiency. 2003 , 9, 369-74		8
813	Medical management of patients with an acute stroke: treatment and prevention. 2003 , 10, 34-45		48
812	hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation. 2003 , 5, 2-7		40
811	Thrombin, inflammation, and cardiovascular disease: an epidemiologic perspective. 2003 , 124, 49S-57S		80
810	Changes in tissue factor and activated factor XII following an acute myocardial infarction were uninfluenced by high doses of n-3 polyunsaturated fatty acids. 2003 , 89, 752-759		10

809	Potential role of statins in inflammation and atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2003 , 10, 140-4	4	42
808	Dose Dependent Changes of Lipid Profiles, IL-6 and CRP in Unstable Angina Patients after Simvastatin Therapy. 2003 , 33, 663		4
807	Inflammation and coronary artery disease. 2003 , 1, 65-70		55
806	C-reactive protein: a surrogate risk marker or mediator of atherothrombosis?. 2003 , 285, R1250-2		29
805	Development of Anti-Inflammatory Drugs for Cardiovascular Disease. 2003 , 87-106		
804	Estrogen and stroke: a balanced analysis. 2003 , 34, 338-41		117
803	Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2004 , 11, 253-64	4	82
802	History and Biochemistry of Statins. 2004 , 1-12		
801	Statins, Inflammation, and C-Reactive Protein. 2004 , 219-232		
800	Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. 2004 , 92, 1129-35		34
799	Global analysis of RNA expression profile in human vascular cells treated with statins. <i>Journal of Atherosclerosis and Thrombosis</i> , 2004 , 11, 62-72	4	59
798	C-Reactive Protein as a Marker for Cardiovascular Disease. 2004 , 39, 735-744		1
797	New nonlipid effects of statins and their clinical relevance in cardiovascular disease. 2004 , 91, 1065-77		45
796	C-reactive protein increase in acute myocardial infarction. 2004 , 59, 291-6		20
795	Identifying patients at risk of coronary vascular disease: the potential role of inflammatory markers. 2004 , 6, C21-C27		5
794	Nontraditional risk factors for cardiovascular disease in diabetes. 2004 , 25, 153-75		126
793	Statins and cardiac allograft vasculopathy after heart transplantation. 2004 , 4, 401-6		18
792	[Emerging risk factors for cardiovascular disease]. 2004 , 129, 204-9		0

791	Inflammation as a cardiovascular risk factor. <i>Circulation</i> , 2004 , 109, II2-10	16.7	670
790	Defining the balance of risk and benefit in the era of genomics and proteomics. 2004 , 23, 77-87		21
789	Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. 2004 , 27, 468-73		33
788	CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. <i>Circulation</i> , 2004 , 110, e560-7	16.7	131
787	Role of C-reactive protein in cardiovascular disease. 2004 , 38, 110-8		50
786	Inflammation in atherosclerosis and implications for therapy. <i>Circulation</i> , 2004 , 109, III20-6	16.7	214
785	Beneficial cardiovascular pleiotropic effects of statins. <i>Circulation</i> , 2004 , 109, III39-43	16.7	556
784	Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). <i>Circulation</i> , 2004 , 109, 726-32	16.7	319
783	The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. 2004 , 62, 105-11		204
782	Predictive value of elevated white blood cell count in patients with preexisting coronary heart disease: the Bezafibrate Infarction Prevention Study. 2004 , 164, 433-9		46
781	C-reactive protein is associated with arterial stiffness in apparently healthy individuals. 2004 , 24, 969-74		309
780	Beyond the laboratory: clinical implications for statin pleiotropy. <i>Circulation</i> , 2004 , 109, II42-8	16.7	127
779	Statins for stroke prevention: disappointment and hope. <i>Circulation</i> , 2004 , 109, III44-9	16.7	42
778	Nitric Oxide, Atherosclerosis and the Clinical Relevance of Endothelial Dysfunction. 2004 , 55-70		
777	Ultrasound and arterial wall disease. 2004 , 17 Suppl 1, 19-33		48
776	Improving outcomes through statin therapy ? a review of ongoing trials. 2004 , 6, A28-A31		8
775	Chapter 10 Risk Factor Modification for Secondary Prevention. 2004 , 29, 197-210		
774	Statins in patients at high risk of cardiovascular disease presenting with peripheral artery disease. 2004 , 25, 712-3		1

773	Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting. 2004 , 25, 1029-35		30
772	Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin. 2004 , 109, 71-122		2
771	Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. 2004 , 18, 805-15		68
770	Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. <i>Circulation</i> , 2004 , 109, IV6-19	16.7	246
769	Incidence of high-strain patterns in human coronary arteries: assessment with three-dimensional intravascular palpography and correlation with clinical presentation. <i>Circulation</i> , 2004 , 109, 2716-9	16.7	127
768	Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. 2004 , 279, 16154-60		157
767	Pleiotropic Effects of Statins. 2004 , 39, 239-258		2
766	Inflammation, dyslipidaemia, diabetes and PPARs: pharmacological interest of dual PPARalpha and PPARgamma agonists. 2004 , 58, 22-9		29
765	Cardioprotective and other emerging effects of statins. 2004 , 58, 49-57		7
764	C-reactive protein and risk factors for peripheral vascular disease in subjects with Type 2 diabetes mellitus. 2004 , 21, 336-41		26
763	Periodontitis and atherogenesis: causal association or simple coincidence?. 2004 , 31, 402-11		101
762	Long-term effects of a high-protein, low-carbohydrate diet on weight control and cardiovascular risk markers in obese hyperinsulinemic subjects. 2004 , 28, 661-70		177
761	Statins in solid organ transplantation: is there an immunosuppressive effect?. 2004 , 4, 1013-8		46
760	High-sensitivity C-reactive protein: Clinical importance. 2004 , 29, 439-493		14
759	Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation. 2004 , 93, 92-5		10
758	Effect of simvastatin on serum C-reactive protein during hormone replacement therapy. 2004 , 93, 217-8		3
757	Early effects of statins in patients with coronary artery disease and high C-reactive protein. 2004 , 94, 1107-12		21
756	Vascular disease and inflammation. 2004 , 22, 183-97, v		1

755	Vitamin E modulation of C-reactive protein in smokers with acute coronary syndromes. 2004 , 36, 959-65	31
754	Should standard medical therapy for angina include a statin?. 2004 , 27, 547-51	3
753	Inflammation and cardiovascular risk: An overview. 2004 , 13, 161-167	2
752	[Rheumatoid arthritis, inflammation, and atherosclerosis]. 2004 , 29, 760-8	25
751	[Lifelong after-care and secondary prevention after myocardial infarct]. 2004 , 99, 309-20; quiz 321	
750	Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial. 2004 , 35, 2807-12	121
749	Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. 2004 , 35, 2902-9	556
748	La inflamaci3n en los s3ndromes coronarios agudos: mecanismos e implicaciones cl3nicas. 2004 , 57, 433-446	19
747	Inflamaci3n, disfunci3n endotelial e hipertensi3n arterial. 2004 , 21, 347-354	
746	Impact of kidney transplantation on the progression of cardiovascular disease. 2004 , 11, 274-93	6
745	Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. <i>Circulation</i> , 2004 , 110, 214-9	16.7 365
744	Efecto de la administraci3n precoz de pravastatina en los valores de prote3na C reactiva y de interleucina 6 en la fase aguda del infarto de miocardio con elevaci3n del segmento ST. 2004 , 57, 916-923	0
743	Inflammation in Acute Coronary Syndromes: Mechanisms and Clinical Implications. 2004 , 57, 433-446	3
742	Effect of the Early Administration of Pravastatin on C-Reactive Protein and Interleukin-6 Levels in the Acute Phase of Myocardial Infarction With ST Segment Elevation. 2004 , 57, 916-923	
741	Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. 2004 , 43, 169-75	78
740	Reduction in C-reactive protein through cardiac rehabilitation and exercise training. 2004 , 43, 1056-61	241
739	Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease. 2004 , 44, 44-9	90
738	Leukocyte count and coronary heart disease: implications for risk assessment. 2004 , 44, 1945-56	447

737	Fluvastatin: clinical and safety profile. 2004 , 64, 1305-23	19
736	Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis. 2004 , 64, 2379-88	13
735	Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation. 2004 , 3, 4	121
734	Statins in hypertensive patients: potential explanations for the ASCOT-LLA study results. 2004 , 64 Suppl 2, 61-7	5
733	C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. 2004 , 350, 1387-97	2317
732	Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. 2004 , 33, 431-53, table of contents	93
731	Quality specifications and the assessment of the biochemical risk of atherosclerosis. 2004 , 346, 55-64	11
730	Serum high sensitivity C-reactive protein is associated with carotid intima-media thickness in type 2 diabetes. 2004 , 66 Suppl 1, S115-20	28
729	Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. 2004 , 15, 66-72	46
728	Shear stress-dependent platelet function after LDL cholesterol apheresis. 2004 , 113, 395-8	12
727	Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces delayed neuronal death following transient forebrain ischemia in the adult rat hippocampus. 2004 , 362, 122-6	23
726	Does aggressive statin therapy offer improved cholesterol-independent benefits compared to conventional statin treatment?. 2004 , 96, 131-9	9
725	Reduced creatine kinase release with statin use at the time of myocardial infarction. 2004 , 96, 461-6	11
724	Effects of progestins on estrogen-induced increase in C-reactive protein in postmenopausal women. 2004 , 49, 315-20	12
723	C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. 2004 , 62, 499-506	167
722	High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. 2004 , 148, S19-26	188
721	Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: rationale and design of the DECREASE-IV study. 2004 , 148, 1047-52	57
720	C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. 2004 , 117, 499-507	122

719	The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. 2004 , 13, 125-38	191
718	[The dawn of a new era in cardiovascular prevention]. 2004 , 33, 1126-8	
717	Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. 2004 , 63, 1571-5	102
716	Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. 2004 , 65, 1009-16	512
715	Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy. 2004 , 172, 121-5	20
714	A persistent increase in C-reactive protein is a risk factor for restenosis in patients with stable angina who are not receiving statins. 2004 , 173, 285-90	18
713	Role of Statins in the Treatment and Prevention of Stroke: Introduction. 2004 , 35, 2706-2707	7
712	C-reactive protein for the prediction of cardiovascular risk: ready for prime-time?. 2004 , 170, 1563-5	6
711	Inflammation and cardiovascular diseases: lessons that can be learned for the patient with cardiogenic shock in the intensive care unit. 2004 , 10, 347-53	9
710	Management of the acute coronary syndrome patient. 2004 , 6, C49-C57	
709	Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K ⁺ channels. 2004 , 15, 53-8	27
708	Prevention of restenosis after stenting: the emerging role of inflammation. 2004 , 15, 307-11	38
707	Evidence for anti-inflammatory activity of statins and PPAR α activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. 2004 , 103, 4188-94	152
706	High-sensitivity C-reactive protein: Clinical importance. 2004 , 29, 439-493	30
705	Comparison of Ticlopidine and Aspirin versus Clopidogrel and Aspirin after Percutaneous Coronary Interventions in High-Risk Patients. 2005 , 5, 187-192	
704	Pathogenesis of the Vulnerable Atherosclerotic Plaque. 2005 , 365-375	
703	Role of inflammation and infection in vascular disease. 2005 , 105, 567-79	39
702	The effects of prior beta-blocker therapy on serum C-reactive protein levels after percutaneous coronary intervention. 2005 , 28, 243-6	11

701	High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. 2005 , 28, 408-12	59
700	C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy. 2005 , 68, 773-8	14
699	Glucose intolerance is associated with C-reactive protein and intima-media anatomy of the common carotid artery in patients with coronary heart disease. 2005 , 22, 1212-7	10
698	High levels of C-reactive protein with low total cholesterol concentrations additively predict all-cause mortality in patients with coronary artery disease. 2005 , 35, 104-11	5
697	Statins and cancer prevention. 2005 , 5, 930-42	621
696	Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. 2005 , 4, 977-87	619
695	Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. 2005 , 29, 1452-6	105
694	Large artery stiffness and inflammation. 2005 , 19, 507-9	52
693	Improved Cerebral Vasoreactivity After Statin Administration in Healthy Adults. 2005 , 15, 266-270	27
692	Early initiation of statin therapy in acute coronary syndromes: a review of the evidence. 2005 , 18, 55-63	6
691	Complement activation in acute coronary syndromes. 2005 , 113, 167-74	27
690	Pharmacogenomics and cardiovascular drugs: need for integrated biological system with phenotypes and proteomic markers. 2005 , 527, 1-22	27
689	Statins and autoimmune diseases. 2005 , 4, 123-9	21
688	B-type natriuretic peptide and long-term survival in patients with stable coronary artery disease. 2005 , 95, 24-8	50
687	Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent (results from the prospective multicenter German Cypher Stent Registry). 2005 , 95, 1302-8	62
686	Relation of number of complex coronary lesions to serum C-reactive protein levels and major adverse cardiovascular events at one year. 2005 , 96, 56-60	34
685	Relation of C-reactive protein and one-year survival after acute myocardial infarction with versus without statin therapy. 2005 , 96, 617-21	19
684	Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus, and preexisting cardiovascular disease. 2005 , 96, 655-8	51

683	Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. 2005 , 96, 24F-33F		200
682	Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. 2005 , 45, 2-14		89
681	Pharmacological treatment of ischemic stroke. 2005 , 108, 334-52		7
680	Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels. 2005 , 25, 1365-77		7
679	Interaction between simvastatin and metoprolol with respect to cardiac beta-adrenoceptor density, catecholamine levels and perioperative catecholamine requirements in cardiac surgery patients. 2005 , 372, 115-24		15
678	[The role of inflammation in the pathophysiology of acute coronary syndromes]. 2005 , 117, 445-55		8
677	Platelets and atherothrombosis: An essential role for inflammation in vascular disease [A review. 2005 , 14, 211-217		2
676	Novel serologic markers of cardiovascular risk. 2005 , 7, 148-54		9
675	Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk. 2005 , 7, 22-8		7
674	Using biomarkers to assess risk and consider treatment strategies in non-ST-segment elevation acute coronary syndromes. 2005 , 7, 263-9		1
673	HMG-CoA reductase inhibitors and the kidney. 2005 , 7, 337-42		3
672	Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696]. 2005 , 6, 4		11
671	The relation between hypoalbuminemia and compliance and intima-media thickness of carotid artery in continuous ambulatory peritoneal dialysis patients. 2005 , 20, 70-4		5
670	Effect of statin on restenosis after radius stent implantation in patients with acute coronary syndrome. <i>Journal of Atherosclerosis and Thrombosis</i> , 2005 , 12, 302-6	4	1
669	The Long-Term Clinical Outcomes of Combination Therapy with Angiotensin II Type 1 Receptor Blocker and Simvastatin after Percutaneous Coronary Intervention. 2005 , 35, 877		3
668	HMG-CoA reductase inhibitors suppress the development and progression of carotid artery intimal-medial thickening in hypercholesterolemic type 2 diabetic patients. <i>Journal of Atherosclerosis and Thrombosis</i> , 2005 , 12, 149-53	4	14
667	White blood cell count predicts reduction in coronary heart disease mortality with pravastatin. <i>Circulation</i> , 2005 , 111, 1756-62	16.7	54
666	[Stroke--possibilities for prevention]. 2005 , 50, 233-7		

665	Peptides derived from serum amyloid A prevent, and reverse, aortic lipid lesions in apoE ^{-/-} mice. 2005 , 46, 2091-101		33
664	The effect of intensive lipid lowering on coronary atheroma and clinical outcome. 2007 , 93, 149-51		4
663	Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?. 2005 , 16 Suppl 1, S11-7		47
662	C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. <i>Circulation</i> , 2005 , 112, 1289-95	16.7	82
661	Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?. 2005 , 46, 389-403		172
660	Effect of simvastatin, an established lipid-lowering drug, on pulmonary <i>Chlamydia pneumoniae</i> infection in mice. 2005 , 49, 3959-62		46
659	Lipids and stroke: the opportunity of lipid-lowering treatment. 2005 , 20 Suppl 2, 53-67		13
658	Inflammation in atherosclerosis: new opportunities for drug discovery. 2005 , 5, 33-40		4
657	Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease: Randomized and Observational Comparisons of Secondary Prevention Trials and Their Meta-analyses. 2005 , 17, 65-1-67		1
656	Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease. 2005 , 3, 743-59		8
655	Serum amyloid A and lipoprotein retention in murine models of atherosclerosis. 2005 , 25, 785-90		96
654	Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. 2005 , 172, 1199-209		154
653	Ambient particulate matter, C-reactive protein, and coronary artery disease. 2005 , 17, 409-13		27
652	Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target. 2005 , 14, 671-9		17
651	<i>Helicobacter pylori</i> infection causes persistent platelet activation in vivo through enhanced lipid peroxidation. 2005 , 25, 246-51		25
650	Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. 2005 , 36, 1316-29		226
649	Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis. 2005 , 5, 127-34		32
648	Fluctuating inflammatory markers in patients with stable ischemic heart disease. 2005 , 165, 221-6		48

647	C-reactive protein predicts death in patients with non-ischemic cardiomyopathy. 2005 , 104, 196-201	10
646	Elevated C-reactive protein levels and coronary microvascular dysfunction in patients with coronary artery disease. 2005 , 26, 2099-105	46
645	Effect of exercise training on plasma levels of C-reactive protein in healthy adults: the HERITAGE Family Study. 2005 , 26, 2018-25	145
644	Evolution of C-Reactive Protein as a Cardiac Risk Factor. 2005 , 36, 234-238	3
643	Inflamaci3n y arteriosclerosis. 2005 , 22, 173-182	
642	Marcadores biol3gicos de inflamaci3n y control del tratamiento hipolipemiante. 2005 , 17, 25-30	
641	Diet-induced weight loss is associated with decreases in plasma serum amyloid a and C-reactive protein independent of dietary macronutrient composition in obese subjects. 2005 , 90, 2244-9	92
640	[What explains the increased rate of thromboses among the elderly? Pathophysiological data]. 2005 , 34, 887-95	0
639	Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. 2005 , 179, 361-7	62
638	What causes acute coronary syndromes? Applying Koch's postulates. 2005 , 179, 1-15	24
637	Plasma homocysteine predicts progression of atherosclerosis. 2005 , 181, 159-65	68
636	Inflammatory markers and long-term risk of ischemic heart disease in men A 13-year follow-up of the Quebec Cardiovascular Study. 2005 , 182, 315-21	58
635	Markers of inflammation and their clinical significance. 2005 , 6, 21-9	108
634	Changes in flow-mediated dilatation, cytokines and carotid arterial stenosis during aggressive atorvastatin treatment in normocholesterolemic patients. 2005 , 68, 53-8	6
633	The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. 2005 , 45, 657-87	525
632	Traditional and emerging risk factors for cardiovascular disease. 2005 , 32, 963-76, vii	13
631	Valoraci3n de la prote3na C reactiva en pacientes con arteriopat3a perif3rica. Modificaciones con tratamiento antiagregante. 2005 , 57, 5-18	2
630	Inflamaci3n y arteriosclerosis. 2005 , 22, 173-182	

629	Place of drug therapy in the treatment of carotid stenosis. 2005 , 19, 597-622	4
628	Statins and the response to myocardial injury. 2005 , 5, 163-70	12
627	Statins and fibrates for preventing melanoma. 2005 , CD003697	25
626	C-reactive protein comes of age. 2005 , 2, 29-36; quiz 58	150
625	C-reactive protein levels and prevalence of chronic infections in subjects with hypoalphalipoproteinemia. 2005 , 54, 33-7	9
624	Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. 2005 , 52, 262-7	294
623	Prognostic value of C-reactive protein in patients with stress induced myocardial ischemia. 2005 , 98, 313-7	6
622	Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. 2005 , 98, 199-206	61
621	Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. 2005 , 24, 1736-40	140
620	Role of hs-CRP measurements in the current cardiovascular risk assessment. 2005 , 355, 215-8	5
619	Evaluation of fluorescence hs-CRP immunoassay for point-of-care testing. 2005 , 356, 172-7	45
618	Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. 2005 , 69, 151-9	55
617	Statins in acute coronary syndromes: the sooner, the better?. 2005 , 149, 377-80	3
616	Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting. 2005 , 150, 550-6	17
615	The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part I. 2005 , 149, 971-6	11
614	The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part II. 2005 , 149, 977-83	20
613	[C-reactive protein changes with antihypertensive and statin treatment]. 2005 , 125, 561-4	3
612	The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. 2005 , 6, 82	134

611	Toward the development of a lab-on-a-chip dual-function leukocyte and C-reactive protein analysis method for the assessment of inflammation and cardiac risk. 2005 , 51, 2391-5	27
610	C-reactive protein levels and outcomes after statin therapy. 2005 , 352, 20-8	1802
609	Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol. 2005 , 45, 1644-8	189
608	Prospects for personalized cardiovascular medicine: the impact of genomics. 2005 , 46, 1615-27	56
607	Pleiotropic effects of statins. 2005 , 45, 89-118	1303
606	Markers of cardiac ischemia and inflammation. 2005 , 23, 491-501, vi	4
605	Biomarkers of cardiac injury: an update. 2005 , 56, 677-91	67
604	Therapy insight: Potential of statins for cancer chemoprevention and therapy. 2005 , 2, 82-9	93
603	Cardiovascular Biomarkers. 2006 ,	2
602	Novel therapeutic strategies for large vessel vasculitis. 2006 , 32, 173-86, xi	22
601	Present and future biochemical markers for detection of acute coronary syndrome. 2006 , 43, 427-95	14
600	Antioxidants and Cardiovascular Disease. 2006 ,	3
599	Anti-Inflammatory and Antioxidant Functions of High Density Lipoproteins. 2006 , 399-436	
598	Is atrial fibrillation an inflammatory disorder?. 2006 , 27, 136-49	424
597	Utilidad de los marcadores de inflamaci3n en el diagn3stico del riesgo cardiovascular. 2006 , 18, 56-71	
596	C-Reactive Protein Concentration in Dogs with Chronic Valvular Disease. 2006 , 20, 635-639	35
595	A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease. 2006 , 7, 21-9	4
594	Statins: potential new indications in inflammatory conditions. 2006 , 7, 31-5	94

593	Serum markers of vascular inflammation in dyslipemia. 2006 , 369, 1-16	44
592	Inflammation, Atherosclerosis, and Cardiovascular Disease Risk: PAPP-A, Lp-PLA2, and Cystatin C. New Insights or Redundant Information?. 2006 , 59, 247-258	4
591	Inflamaci3n, aterosclerosis y riesgo cardiovascular: PAPP-A, Lp-PLA2 y cistatina C. ¿Nuevas aportaciones o informaci3n redundante?. 2006 , 59, 247-258	19
590	[Impact of metabolic syndrome on CRP levels]. 2006 , 206, 363-8	2
589	Physical activity and high-sensitivity C-reactive protein. 2006 , 36, 443-58	161
588	C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. 2006 , 47, C19-31	249
587	Inflammation and Atherothrombosis. 2006 , 48, A33-A46	129
586	Effects of lifestyle modifications on C-reactive protein: contribution of weight loss and improved aerobic capacity. 2006 , 55, 825-31	46
585	High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. 2006 , 29, 329-33	120
584	The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome. 2006 , 368, 183-7	13
583	The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. 2006 , 106, 291-7	150
582	Reduced risks of death and CHF are associated with statin therapy administered acutely within the first 24 h of AMI. 2006 , 108, 314-9	15
581	A comparative study of markers of inflammation for the assessment of cardiovascular risk in patients presenting to the emergency department with acute chest pain suggestive of acute coronary syndrome. 2006 , 109, 317-21	22
580	Carotid atherosclerotic plaque instability in patients with acute myocardial infarction. 2006 , 111, 263-6	28
579	Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women. 2006 , 113, 66-75	4
578	Obesity as an inflammatory condition. 2006 , 11,	0
577	Effect of combination therapy with simvastatin and carvedilol in patients with left ventricular dysfunction complicated with acute myocardial infarction who underwent percutaneous coronary intervention. 2006 , 70, 1269-74	9
576	Inflammation and cardiovascular disease mechanisms. 2006 , 83, 456S-460S	720

575	Predictive value of C-reactive protein and left ventricular diastolic filling pattern after a non-ST elevation myocardial infarction. 2006 , 331, 113-8	5
574	Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension. 2006 , 47, 508-12	7
573	Atherosclerosis, inflammation, leukocyte function and the effect of statins. 2006 , 24, 2349-51	10
572	High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors. 2006 , 24, 655-61	32
571	Relationship between low-grade inflammation and arterial stiffness in patients with essential hypertension. 2006 , 24, 2231-8	74
570	Protective role of chronic statin therapy in reducing myocardial damage during percutaneous coronary intervention. 2006 , 7, 416-21	6
569	Statins and the acute coronary syndrome: The early bird catches the worm 2006 , 60, 716-27	4
568	Cardiovascular trials of estrogen replacement therapy. 2001 , 949, 153-62	16
567	Inflammatory biomarkers and cardiovascular risk: association or cause and effect?. 2006 , 19, 129-35	24
566	Statins and bone metabolism. 2006 , 12, 85-101	83
565	Atorvastatin inhibits inflammatory hypernociception. 2006 , 149, 14-22	58
564	Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel. 2006 , 149, 243-9	38
563	Effects of withdrawal of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with coronary artery disease. 2006 , 20, 185-91	13
562	The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol. 2006 , 21, 291-7	21
561	Other than potency, are all statins the same?. 2006 , 8, 26-31	1
560	Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?. 2006 , 32, 286-93	102
559	Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?. 2006 , 97, 33A-41A	156
558	Usefulness of preoperative C-reactive protein and soluble intercellular adhesion molecule-1 level for predicting future cardiovascular events after coronary artery bypass grafting. 2006 , 97, 1697-701	14

557	Inflammatory biomarkers in stable atherosclerosis. 2006 , 98, 2P-8P	59
556	Atherosclerosis: its cause and its prevention. 2006 , 98, 1550-5	12
555	Pathophysiology, diagnosis, and management of dyslipidemia. 2006 , 31, 445-86	17
554	Prevención y tratamiento del síndrome coronario agudo. 2006 , 6, 36G-45G	0
553	C-reactive protein and the metabolic syndrome: useful addition to the cardiovascular risk profile?. 2006 , 1, 66-9; quiz 70-1	10
552	Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. 2006 , 20, 14-20	21
551	Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?. 2006 , 79, 1-33	98
550	Update on lipid-lowering therapy and LDL-cholesterol targets. 2006 , 3, 424-36	7
549	Novel anti-inflammatory drugs in hypertension. 2006 , 21, 859-64	8
548	The predictive value of C-reactive protein in end-stage renal disease: is it clinically significant?. 2006 , 24, 335-41	18
547	Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort. 2006 , 174, 461-6	40
546	Atherosclerosis is an inflammatory disorder after all. 2006 , 6, 93-102	9
545	Cardiovascular disease could be contained based on currently available data!. 2006 , 4, 225-54	2
544	Potential therapeutic role for statins in respiratory disease. 2006 , 61, 729-34	125
543	Inflammatory Markers in Coronary Artery Disease: Pathophysiological Mechanisms, Prognostic and Therapeutic Implications. 2006 , 2, 173-184	1
542	New anti-inflammatory agents to reduce atherosclerosis. 2006 , 112, 130-7	2
541	High Sensitivity C-Reactive Protein (hsCRP): A New Biochemical Marker of Atherosclerotic Vascular Disease. 2006 , 2, 215-225	
540	Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. 2006 , 26, 977-86	134

539 C-Reactive Protein as a Tool for Risk Assessment in Primary Prevention. **2006**, 237-260

538 Brain Embolism. **2006**, 9

537 Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. *Circulation*, **2006**, 114, 281-8 16.7 239

536 "Anti-inflammatory" drugs and their effects on type 2 diabetes. **2006**, 8, 18-27 34

535 National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. **2007**, 53, 552-74 326

534 Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. *Circulation*, **2007**, 115, 2715-21 16.7 186

533 C-reactive protein and reendothelialization: NO involvement. **2007**, 100, 1405-7 2

532 Impact of C-reactive protein on treatment of patients with cardiovascular disease. **2007**, 64, 2009-16 10

531 C-reactive protein: interaction with the vascular endothelium and possible role in human atherosclerosis. **2007**, 13, 1631-45 65

530 Do statins have an antiarrhythmic activity?. **2007**, 75, 10-20 49

529 Beneficial effects of statins on endothelial dysfunction and vascular stiffness. **2007**, 5, 227-37 53

528 Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. **2007**, 9, 724-9 62

527 Cerebral vascular dysfunction during hypercholesterolemia. **2007**, 38, 2136-41 75

526 Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. **2007**, 107, 117-21 72

525 Impact of simvastatin and losartan on antiinflammatory effect: in vitro study. **2007**, 49, 20-6 19

524 Hormonal and nutritional effects on cardiovascular risk markers in young women. **2007**, 92, 3089-94 17

523 The plasma concentration of advanced oxidation protein products and arterial stiffness in apparently healthy adults. **2007**, 41, 645-9 14

522 Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. *Circulation*, **2007**, 115, 1528-36 16.7 262

521	C-Reactive Protein and Cardiovascular Risk in the Metabolic Syndrome and Type 2 Diabetes: Controversy and Challenge. 2007 , 25, 16-22		8
520	Simvastatin protects against multiple low-dose streptozotocin-induced type 1 diabetes in CD-1 mice and recurrence of disease in nonobese diabetic mice. 2007 , 323, 180-5		25
519	C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). <i>Circulation</i> , 2007 , 115, 981-9	16.7	100
518	Saving the ischemic penumbra: potential role for statins and phosphodiesterase inhibitors. 2007 , 5, 259-65		7
517	Leukocyte count and vascular risk in symptomatic intracranial atherosclerosis. 2007 , 24, 283-8		20
516	Infection as a risk factor for stroke. 2007 , 2, 59-71		
515	Upstream therapy for atrial fibrillation. 2007 , 71 Suppl A, A75-81		4
514	Inflammation and ischaemic stroke. 2007 , 20, 334-42		192
513	Statins and perioperative myocardial infarction. Mechanisms of action. 2007 , 13, 33-43		
512	The mevalonate pathway as a therapeutic target in the Ph-negative chronic myeloproliferative disorders. 2007 , 8, 247-56		5
511	C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease. 2007 , 154, 1095-101		10
510	C-reactive protein: a nontraditional serum marker of cardiovascular risk. 2007 , 16, 14-21		122
509	Role of inflammation in atherosclerosis. 2007 , 48, 1800-15		152
508	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. <i>Circulation</i> , 2007 , 115, e356-75	16.7	255
507	Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. 2007 , 7, 219-24		45
506	Lipoprotein-associated phospholipase A(2) : review of its role as a marker and a potential participant in coronary endothelial dysfunction. 2007 , 11, 219-26		15
505	Plasma concentrations of C-reactive protein and total homocysteine in relation to the severity and risk factors for cerebrovascular disease. 2007 , 150, 158-63		21
504	C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. 2007 , 49, 2129-38		453

503	Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. 2007 , 50, 852-8	199
502	Obesity, Inflammation, and Vascular Disease. 2007 , 63-91	64
501	Intake of fish oil, oleic acid, folic acid, and vitamins B-6 and E for 1 year decreases plasma C-reactive protein and reduces coronary heart disease risk factors in male patients in a cardiac rehabilitation program. 2007 , 137, 384-90	36
500	Primary Prevention of Ischemic Heart Disease. 2007 , 178-220	1
499	Proteína C reativa e instabilidade clíica na doenã obstrutiva de artãas cardãdas. 2007 , 6, 124-129	
498	Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity?. 2007 , 40, 229-235	10
497	Effect of Conventional Dose of Simvastatin on Plaque Regression and Vascular Remodeling in the Persistent Reference Segments of Normocholesterolemic Patients: A Serial Intravascular Ultrasound Assessment. 2007 , 37, 483	2
496	Inflammation markers as mediators of vasculo-endothelial dysfunction and atherosclerosis in the metabolic syndrome and type 2 diabetes. 2007 , 120, 1918-1924	6
495	Comparison and evaluation of two C-reactive protein assays based on particle-enhanced immunoturbidimetry. 2007 , 21, 71-6	21
494	S100B in neuropathologic states: the CRP of the brain?. 2007 , 85, 1373-80	188
493	CD59 or C3 are not required for angiotensin II-dependent hypertension or hypertrophy in mice. 2007 , 121, 518-25	9
492	Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. 2007 , 27, 1619-26	60
491	Role of C-reactive protein in coronary risk reduction: focus on primary prevention. 2007 , 99, 718-25	35
490	Effect of early statin treatment at standard doses on long-term clinical outcomes in patients with acute myocardial infarction (the Heart Institute of Japan, Department of Cardiology Statin Evaluation Program). 2007 , 99, 1523-8	28
489	Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol. 2007 , 100, 1548-51	15
488	Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. 2007 , 100, 1659-64	100
487	Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events. 2007 , 38, 479-88	30
486	Simvastatin stimulates macrophage interleukin-1beta secretion through an isoprenylation-dependent mechanism. 2007 , 46, 91-6	22

485	From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention. 2007 , 113, 184-96	35
484	Lack of synergistic effects of metabolic syndrome and plasma fibrinogen on coronary events and mortality in moderate CKD. 2007 , 49, 356-64	7
483	Glycemic control modifies the association between microalbuminuria and c-reactive protein in Type 2 Diabetes Mellitus. 2007 , 22, 53-9	3
482	The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. 2007 , 63, 113-21	36
481	Anti-inflammatory effects of pravastatin on Helicobacter pylori-induced gastritis in mice. 2007 , 52, 2833-9	10
480	The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. 2007 , 30, 230-5	30
479	High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. 2007 , 42, 573-82	193
478	Lipid-independent pleiotropic effects of statins in the management of acute coronary syndromes. 2007 , 9, 46-51	6
477	Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. 2008 , 23, 91-5	37
476	Using inflammatory biomarkers to guide lipid therapy. 2008 , 2, 29-34	2
475	IL1B gene promoter haplotype pairs predict clinical levels of interleukin-1beta and C-reactive protein. 2008 , 123, 387-98	65
474	Association of high sensitivity C-reactive protein (hsCRP) and tumour necrosis factor-alpha (TNF-alpha) with carotid intimal medial thickness in subjects with different grades of glucose intolerance--the Chennai Urban Rural Epidemiology Study (CURES-31). 2008 , 41, 480-5	22
473	Atorvastatin administration after percutaneous coronary intervention in patients with coronary artery disease and normal lipid profiles: impact on plasma adiponectin level. 2008 , 31, 253-8	19
472	Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. 2007 , 65, S253-9	105
471	Comparison of usefulness of C-reactive protein versus white blood cell count to predict outcome after primary percutaneous coronary intervention for ST elevation myocardial infarction. 2008 , 101, 446-51	32
470	Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria. 2008 , 102, 223-5	4
469	Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial. 2008 , 102, 1023-7	15
468	Plaque biology: interesting science or pharmacological treasure trove?. 2008 , 36, 507-16	6

467	Elevated levels of homocysteine predict cardiovascular death, nonfatal myocardial infarction, and symptomatic bypass graft disease at 2-year follow-up following coronary artery bypass surgery. 2008 , 11, 95-9	5
466	Cerebral small vessel disease and C-reactive protein: results of a cross-sectional study in community-based Japanese elderly. 2008 , 264, 43-9	35
465	Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. 2008 , 359, 2195-207	4661
464	Molecular mechanism of PPAR in the regulation of age-related inflammation. 2008 , 7, 126-36	92
463	Independent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable angina. 2008 , 196, 779-85	37
462	Markers of inflammation and coronary artery calcification: a systematic review. 2008 , 201, 1-7	114
461	Short-term effect of atorvastatin on endothelial function in healthy offspring of parents with type 2 diabetes mellitus. 2008 , 26, 253-61	14
460	Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein. 2008 , 83, 333-42	37
459	Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. 2009 , 30, 827-33	48
458	Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease. <i>Circulation</i> , 2008 , 117, 163-168	16.7 562
457	Serum amyloid A as a marker and mediator of acute coronary syndromes. 2008 , 4, 495-504	14
456	The use of high-sensitivity assays for C-reactive protein in clinical practice. 2008 , 5, 621-35	95
455	Simvastatin inhibits catecholamine secretion and synthesis induced by acetylcholine via blocking Na ⁺ and Ca ²⁺ influx in bovine adrenal medullary cells. 2008 , 327, 130-6	8
454	Lipid-lowering therapy is related to inflammatory markers and 3-year mortality in patients with critical limb ischemia. 2008 , 59, 542-8	12
453	Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. 2008 , 74, 1461-7	63
452	The time for cardiovascular inflammation reduction trials has arrived: how low to go for hsCRP?. 2008 , 28, 1222-4	20
451	Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. 2008 , 39, 3297-302	186
450	Endothelial function and inflammation in coronary artery disease. 2006 , 92, 441-4	76

449	Effects of rosuvastatin on cardiovascular morphology and function in an ApoE-knockout mouse model of atherosclerosis. 2008 , 295, H2046-53	25
448	Statins for acute coronary syndrome. 2008 ,	
447	An Evaluation of the Clinical Evidence on the Role of Inflammation and Oxidative Stress in Smoking-Mediated Cardiovascular Disease. 2008 , 3, 127-139	23
446	The role of adiposity as a determinant of an inflammatory milieu. 2008 , 9, 450-60	28
445	Association of statin therapy with reduced coronary plaque rupture: an optical coherence tomography study. 2008 , 19, 237-42	37
444	Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigators. <i>Journal of Atherosclerosis and Thrombosis</i> , 2008 , 15, 345-50	4 38
443	Hypolipidemic and antihypertensive drugs for prevention of cardiovascular complications in patients with rheumatoid arthritis. 2008 ,	
442	The Effects of Rosuvastatin on Plaque Regression in Patients Who Have a Mild to Moderate Degree of Coronary Stenosis With Vulnerable Plaque. 2008 , 38, 366	7
441	Prognostic Biomarkers in Individuals with Prevalent Coronary Heart Disease. 2009 , 26, 265-271	5
440	Inflammation: A Link Between Hypertension and Atherosclerosis. 2009 , 5, 40-48	16
439	The relationship of plasminogen activator inhibitor-1 levels to the ST deviation pattern of acute myocardial infarction. 2009 , 112, 56-9	10
438	The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. 2009 , 55, 219-28	73
437	Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. 2009 , 55, 305-12	70
436	C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. 2009 , 55, 209-15	128
435	Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk. 2009 , 5, 231-6	7
434	Pre-operative high sensitive C-reactive protein predicts cardiovascular events after coronary artery bypass grafting surgery: a prospective observational study. 2009 , 12, 127-32	19
433	Aggressive statin therapy in multicenter and effectiveness for the reduction of intra-myocardial damage caused by non-ST elevation acute coronary syndrome: AMERICA study. 2009 , 3, 357-65	8
432	The JUPITER trial: results, controversies, and implications for prevention. 2009 , 2, 279-85	95

431	Metabolic syndrome abating the beneficial effect of pravastatin treatment on adhesion of endothelium by monocytes in subjects with hypercholesterolemia. 2009 , 58, 416-20		3
430	Inflammatory biomarkers in coronary artery disease. <i>Journal of Cardiology</i> , 2009 , 53, 317-33	3	229
429	Endothelial dysfunction, increased carotid artery intima-media thickness and pulse wave velocity, and increased level of inflammatory markers are associated with variant angina. <i>Journal of Cardiology</i> , 2009 , 54, 183-91	3	20
428	Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. 2009 , 13, 1451-63		108
427	Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). 2009 , 7 Suppl 1, 332-9		219
426	The editor's roundtable: the JUPITER trial--initial results and clinical implications. 2009 , 103, 1417-25		18
425	Vitamin C treatment reduces elevated C-reactive protein. 2009 , 46, 70-7		68
424	Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention. 2009 , 10, 144-50		18
423	Should patients with rheumatoid arthritis receive statin therapy?. 2009 , 60, 1205-9		17
422	Moving toward new statin guidelines in a post-JUPITER world: principles to consider. 2009 , 11, 249-56		17
421	Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease?. 2009 , 4, 25-34		64
420	CRP and the risk of atherosclerotic events. 2009 , 31, 79-94		80
419	Regulation of different inflammatory diseases by impacting the mevalonate pathway. 2009 , 127, 18-25		28
418	Is there a role for statins in atrial fibrillation?. 2009 , 32, 1063-72		6
417	Causes and consequences of inflammation on anemia management in hemodialysis patients. 2009 , 13, 222-34		22
416	Atorvastatin enhances humoral immune responses but does not alter renal injury in experimental crescentic glomerulonephritis. 2009 , 14, 650-7		0
415	Statins as anti-arrhythmics: a systematic review part II: effects on risk of ventricular arrhythmias. 2009 , 32, 549-52		16
414	Multimarker approach predicts adverse cardiovascular events in women evaluated for suspected ischemia: results from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. 2009 , 32, 244-50		16

413	Statins as antiarrhythmics: a systematic review part I: effects on risk of atrial fibrillation. 2009 , 32, 544-8	12
412	Newer risk markers and surrogate endpoints in atherosclerosis management. 2001 , 24, III13-7	4
411	Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice. 2009 , 63, 19-26	17
410	Prothrombin fragment 1 + 2 is associated with intima media thickness of the carotid artery in patients with myocardial infarction. 2009 , 124, 526-30	6
409	Plasma C-reactive protein levels correlate with markers of airway inflammation after lung transplantation: a role for systemic inflammation in bronchiolitis obliterans syndrome?. 2009 , 41, 595-8	7
408	Circulating and intrapulmonary C-reactive protein: a predictor of bronchiolitis obliterans syndrome and pulmonary allograft outcome. 2009 , 28, 799-807	18
407	Effect of statin adherence on cerebrovascular disease in primary prevention. 2009 , 122, 647-55	49
406	Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. 2009 , 54, 2388-95	40
405	Obesity, inflammation, and atherosclerosis. 2009 , 6, 399-409	615
404	Effect of HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors on the concentration of insulin-like growth factor-1 (IGF-1) in hypercholesterolemic patients. 2009 , 61, 654-64	8
403	Statin research in critical illness: hampered by poor trial design?. 2009 , 13, 1015	0
402	Prognostic implications of C-reactive protein and troponin following percutaneous coronary intervention. <i>Canadian Journal of Cardiology</i> , 2009 , 25, e42-7	3.8 16
401	Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. 2009 , 373, 1175-82	734
400	Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. <i>Circulation</i> , 2009 , 120, 2188-96	16.7 138
399	Preinjury statin use is associated with a higher risk of multiple organ failure after injury: a propensity score adjusted analysis. 2009 , 67, 476-82; discussion 482-4	11
398	Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHPELAGO study. 2009 , 30, 2733-41	14
397	Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. 2009 , 116, 497-505	84
396	Regular physical exercise improves physical motor functions and biochemical markers in middle-age and elderly women. 2009 , 6, 55-62	14

395	C-reactive protein and cardiovascular diseases--is it ready for primetime?. 2009 , 338, 486-92		65
394	Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. 2009 , 338, 310-8		87
393	Appropriate use of nasal continuous positive airway pressure decreases elevated C-reactive protein in patients with obstructive sleep apnea. 2009 , 136, 125-129		71
392	Management of hypercholesterolemia in older persons for the prevention of cardiovascular disease. 2010 , 18, 132-40		16
391	An update on the role of markers of inflammation in atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010 , 17, 1-11	4	149
390	Predictive value of C-reactive protein after drug-eluting stent implantation. 2010 , 6, 167-79		9
389	Long-term statin therapy affects the severity of chronic gastritis. 2010 , 15, 510-5		19
388	Pravastatin treatment before coronary artery bypass grafting for reduction of postoperative atrial fibrillation. 2010 , 58, 120-5		15
387	Secondary prevention strategies for coronary heart disease. 2010 , 29, 8-24		20
386	Long-term prognostic value of preprocedural C-reactive protein after drug-eluting stent implantation. 2010 , 105, 826-32		23
385	Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA. 2010 , 105, 1284-8		51
384	C-reactive protein, left atrial volume, and atrial fibrillation: a prospective study in high-risk elderly. 2010 , 27, 394-9		17
383	C-reactive protein lowering with rosuvastatin in the METEOR study. 2010 , 268, 155-61		26
382	Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. 2010 , 4, 383-413		76
381	Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010 , 17, 722-9	4	33
380	Noncalcified coronary plaque in systemic lupus erythematosus. 2010 , 37, 579-84		25
379	Evidence for statin therapy in polycystic ovary syndrome. 2010 , 1, 15-22		10
378	Cholesterol screening and the Gold Effect. 2010 , 12, 33-50		8

377	Varespladib methyl in cardiovascular disease. 2010 , 19, 1245-55	12
376	Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. 2010 , 8, 835-43	12
375	Genome-wide association study identifies two novel regions at 11p15.5-p13 and 1p31 with major impact on acute-phase serum amyloid A. 2010 , 6, e1001213	20
374	Stents and statins: history, clinical outcomes and mechanisms. 2010 , 8, 1283-95	7
373	C-reactive protein improves risk prediction in patients with acute coronary syndromes. 2010 , 31, 290-7	51
372	Contemporary results of carotid endarterectomy for asymptomatic carotid stenosis. 2010 , 41, 975-9	45
371	The Potential Role of Statins in Pneumonia. 2010 , 6, 155-161	4
370	Traitement pharmacologique de la BPCO. 2010 , 27, S19-S35	0
369	Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering. 2010 , 10 Suppl 1, 3-9	42
368	Enhanced psychosocial well-being following participation in a mindfulness-based stress reduction program is associated with increased natural killer cell activity. 2010 , 16, 531-8	68
367	Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels. 2010 , 10, 383-400	11
366	The association between previous statin use and development of atrial fibrillation in patients presenting with acute coronary syndrome. 2010 , 141, 147-50	19
365	The impact of body mass index on clinical outcomes after acute myocardial infarction. 2010 , 145, 476-80	24
364	[Biomarkers for detection and prediction in acute coronary syndrome]. 2010 , 134, 499-504	1
363	Tumor specific low pH environments enhance the cytotoxicity of lovastatin and cantharidin. 2010 , 297, 182-9	31
362	Effect of exercise training on chronic inflammation. 2010 , 411, 785-93	319
361	Statins in community acquired pneumonia: Evidence from experimental and clinical studies. 2010 , 104, 1081-91	63
360	Atherosclerosis and leukocyte-endothelial adhesive interactions are increased following acute myocardial infarction in apolipoprotein E deficient mice. 2010 , 212, 414-7	15

359	Interpretation of Mendelian randomization studies and the search for causal pathways in atherothrombosis: the need for caution. 2010 , 8, 465-9	4
358	Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: a health technology assessment report. 2010 , 26, 30-9	16
357	Novel mechanistic and clinical implications concerning the safety of statin discontinuation. 2011 , 63, 867-79	12
356	Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. 2011 , 5, 338-67	201
355	Statins for acute coronary syndrome. 2011 , CD006870	14
354	Statins, inflammation and kidney disease. 2011 , 7, 385-97	52
353	Interleukin-1 β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). 2011 , 162, 597-605	598
352	Chronic inflammatory diseases and cardiovascular risk: a systematic review. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 174-82	3.8 180
351	Red cell distribution width and mortality in predominantly African-American population with decompensated heart failure. 2011 , 17, 292-8	35
350	Pivotal role of inflammation in vascular endothelial dysfunction of hyperlipidemic rabbit and effects by atorvastatin. 2011 , 146, 140-4	15
349	C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. 2011 , 377, 469-76	132
348	Inflammatory concepts of obesity. 2011 , 2011, 529061	74
347	High-Sensitivity C-Reactive Protein and Cardiovascular Disease. 2011 , 3, 178-186	
346	Relationship between increased systemic inflammation and impaired aortic elasticity in young patients with prehypertension. 2011 , 16, 55-61	10
345	Anti-inflammatory treatment of acute coronary syndromes. 2011 , 17, 4172-89	14
344	Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization. 2011 , 107, 1710-7	78
343	Statins have an early antiplatelet effect in patients with acute myocardial infarction. 2011 , 22, 103-10	21
342	The Significance of Toll-Like Receptors in the Development of Ischemic Damage. 2011 , 41, 548-553	2

341	Heart rate variability and biomarkers of systemic inflammation in patients with stable coronary heart disease: findings from the Heart and Soul Study. 2011 , 100, 241-7	46
340	Effect of atorvastatin on 5-fluorouracil-induced experimental oral mucositis. 2011 , 67, 1085-100	27
339	Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death. 2011 , 28, 528-31	13
338	After FRANCIS: next steps in the clinical evaluation of varespladib methyl. 2011 , 7, 11-8	5
337	Inflammation as a marker for the prediction of internal carotid artery restenosis following eversion endarterectomy--evidence from clinical studies. 2011 , 62, 535-42	14
336	Drug-induced changes in risk/biomarkers and their relationship with renal and cardiovascular long-term outcome in patients with diabetes. 2011 , 57, 186-95	2
335	The vascular effects of infection in Pediatric Stroke (VIPS) Study. 2011 , 26, 1101-10	55
334	Circulating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk. 2011 , 31, 2338-44	59
333	Hyperlipidemia in Primary Care. 2011 ,	1
332	High-sensitivity C-reactive protein, vascular imaging, and vulnerable plaque: more evidence to support trials of antiinflammatory therapy for cardiovascular risk reduction. 2011 , 4, 195-7	9
331	HMG CoA reduction in patients with average cholesterol concentrations. 2011 , 57, 1072-3	2
330	Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. 2011 , 6, 1316-25	91
329	Effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients. 2011 , 2, 261-5	7
328	Highly sensitive C reactive protein in patients with metabolic syndrome and cardiovascular disease. 2012 , 5, 98	2
327	Determinants of coronary collateral circulation in patients with coronary artery disease. 2013 , 13, 146-51	11
326	The effect of statin therapy on ventricular tachyarrhythmias: a meta-analysis. 2012 , 19, 16-23	11
325	Pharmacogenetic determinants of statin-induced reductions in C-reactive protein. 2012 , 5, 58-65	27
324	Biomarkers of chronic inflammatory state in uremia and cardiovascular disease. 2012 , 2012, 360147	20

323	Role of p67phox in salt-sensitive hypertension. 2012 , 8, 193-193	
322	Acute coronary syndromes as auto-inflammatory disorders. 2012 , 18, 4370-84	7
321	Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. 2012 , 33, 430-2	44
320	Developing alternative methods for determining the incidence, prevalence, and cost burden of coronary heart disease in a corporate population. 2012 , 54, 1026-38	4
319	Phospholipase A2 enzymes and the risk of atherosclerosis. 2012 , 33, 2899-909	97
318	In-hospital Acquired Anemia in Acute Coronary Syndrome. Predictors, In-hospital Prognosis and One-year Mortality. 2012 , 65, 742-748	
317	High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease. 2012 , 31, 733-745	27
316	Statins and other agents for vascular inflammation. 2012 , 56, 1799-806	10
315	PPAR α as a therapeutic target in inflammation-associated diseases. 2012 , 16, 1113-25	37
314	Prognostic value of high-sensitivity C-reactive protein in a population of post-acute coronary syndrome patients receiving optimal medical treatment. 2012 , 19, 1128-37	6
313	Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?. 2012 , 52, 83-92	73
312	Developing and assessing cardiovascular biomarkers. 2012 , 159, 265-76	19
311	Subsequent silent plaque rupture of nonculprit lesion in a patient with acute myocardial infarction. 2012 , 157, e60-2	5
310	Association between high-sensitivity C-reactive protein with arterial stiffness in healthy Korean adults. 2012 , 413, 1419-23	1
309	Red cell distribution width, inflammatory markers and cardiorespiratory fitness: results from the National Health and Nutrition Examination Survey. 2012 , 64, 380-7	39
308	Global Cardiovascular Risk Reduction in People with Diabetes Mellitus and Hypertension. 2012 , 129-141	
307	Biomarkers in cardiovascular clinical trials: past, present, future. 2012 , 58, 45-53	32
306	[High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease]. 2012 , 31, 733-45	35

305	In-hospital acquired anemia in acute coronary syndrome. Predictors, in-hospital prognosis and one-year mortality. 2012 , 65, 742-8	21
304	Diabetes and Hypertension. 2012 ,	0
303	Effects of simvastatin on bleomycin-induced pulmonary fibrosis in female rats. 2012 , 45, 345-50	8
302	Fenofibrate reduces C-reactive protein levels in hypertriglyceridemic patients with high risks for cardiovascular diseases. 2012 , 42, 741-6	6
301	C-reactive protein and nitric oxide levels in ischemic stroke and its subtypes: correlation with clinical outcome. 2012 , 35, 978-84	44
300	Molecular pathways regulating macrophage polarization: implications for atherosclerosis. 2012 , 14, 254-63	50
299	The effect of a high dose of atorvastatin on the occurrence of atrial fibrillation after coronary artery bypass grafting. 2012 , 94, 8-14	22
298	Hemoglobin and B-type natriuretic peptide preoperative values but not inflammatory markers, are associated with postoperative morbidity in cardiac surgery: a prospective cohort analytic study. 2013 , 8, 170	9
297	High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?. 2013 , 62, 397-408	316
296	High-density lipoproteins: a consensus statement from the National Lipid Association. 2013 , 7, 484-525	215
295	High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. 2013 , 168, 5126-34	176
294	Relationship of high-sensitive C-reactive protein with cardiovascular risk factors, clinical presentation and angiographic profile in patients with acute coronary syndrome: an Indian perspective. 2013 , 65, 359-65	7
293	Traditional heart failure medications and sudden cardiac death prevention: a review. 2013 , 18, 412-26	19
292	Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. 2013 , 166, 199-207.e15	276
291	Acute myocardial infarction leads to acceleration of atherosclerosis. 2013 , 229, 18-22	18
290	Pathophysiological roles and clinical importance of biomarkers in acute coronary syndrome. 2013 , 59, 23-63	8
289	Non-surgical periodontal treatment reduces cardiovascular risk in refractory hypertensive patients: a pilot study. 2013 , 40, 681-7	55
288	Sympathetic nervous system: a crucial player modulating residual cardiovascular risk. 2013 , 112, 13-6	3

287	Statins and percutaneous coronary intervention: a complementary synergy. 2013 , 25, 112-22	2
286	Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high-sensitivity C-reactive protein. 2013 , 167, 1848-53	11
285	Microalbuminuria and C-reactive protein as a predictor of coronary artery disease in patients of acute chest pain. 2013 , 4, 37-9	6
284	Effects of atorvastatin on human C-reactive protein metabolism. 2013 , 226, 466-70	9
283	Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?. 2013 , 15, 295	61
282	Chronic inflammatory muscle diseases and risk of coronary artery disease. 2013 , 15, 308	0
281	Inflammatory biomarkers CRP, MCP-1, serum amyloid alpha and interleukin-18 in patients with HTN and dyslipidemia: impact of diabetes mellitus on metabolic syndrome and the effect of statin therapy. 2013 , 36, 550-8	14
280	Emerging anti-inflammatory drugs for atherosclerosis. 2013 , 18, 193-205	29
279	Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein. 2013 , 92, 845-51	15
278	Stable Angina. 2013 , 419-438	
277	Are statins beneficial for viral pneumonia?. 2013 , 41, 1010-1	4
276	Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. 2013 , 2013, 678159	215
275	A review of statin use in patients with acute coronary syndrome in Western and Japanese populations. 2013 , 41, 523-36	10
274	A Comparative Study of the C-Reactive Protein and the ST-Score (ECG) as Prognostic Indicators in Acute Myocardial Infarction in a Rural Resource-Constrained Hospital Setting in Central India: A Cross-Sectional Study. 2013 , 14, 171-8	
273	Pentraxins in nephrology: C-reactive protein, serum amyloid P and pentraxin-3. 2013 , 28, 803-11	37
272	Bamboo salt attenuates CCL4-induced hepatic damage in Sprague-Dawley rats. 2013 , 7, 273-80	15
271	Relationship between inflammatory markers and new cardiovascular events in patients with acute myocardial infarction who underwent primary angioplasty. 2013 , 5, 48-54	3
270	Effects of Low Dose versus High Dose Statin Therapy on the Changes of Endothelial Function and Carotid Intima-Media Thickness in Patients with Variant Angina. 2013 , 21, 58-63	9

269	Role of statins in coronary artery disease. 2013 , 49, 1-6	23
268	Metabolic biomarkers for predicting cardiovascular disease. 2013 , 9, 37-45	22
267	Role of Traditional Heart Failure Medications on Sudden Cardiac Death Prevention in Patients with Cardiomyopathy. 2013 ,	
266	Incorporating biomarkers into clinical trials in cardiovascular medicine. 2014 , 121	
265	Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention). 2014 , 7, 1421-9	39
264	Antiobesity and vasoprotective effects of resveratrol in apoE-deficient mice. 2014 , 17, 310-6	35
263	Everyday Discrimination Prospectively Predicts Inflammation Across 7-Years in Racially Diverse Midlife Women: Study of Women's Health Across the Nation. 2014 , 70, 298-314	76
262	Impact of prior chronic statin therapy and high-intensity statin therapy at discharge on circulating endothelial progenitor cell levels in patients with acute myocardial infarction: a prospective observational study. 2014 , 70, 1181-93	4
261	Imaging Coronary Atherosclerosis. <i>Contemporary Cardiology</i> , 2014 ,	0.1
260	Interleukin 1 α proinflammatory target for preventing atherosclerotic heart disease. 2014 , 22, 176-81	14
259	Plasma levels of high-sensitive C-reactive protein do not correlate with inflammatory activity in carotid atherosclerotic plaques. 2014 , 275, 127-33	14
258	Strategies for vascular disease prevention: the role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA II) and lipoprotein(a) (Lp(a)). 2014 , 28, 281-94	19
257	Targeting inflammation: impact on atherothrombosis. 2014 , 7, 9-18	12
256	Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: pilot study. 2014 , 4, 110-6	25
255	Statins for acute coronary syndrome. 2014 , CD006870	18
254	Inflammation and atherosclerosis--revisited. 2014 , 19, 170-8	133
253	HMG-CoA reductase inhibitors (statins), inflammation, and endothelial progenitor cells--New mechanistic insights of atherosclerosis. 2014 , 40, 295-302	21
252	Novel simvastatin inhalation formulation and characterisation. 2014 , 15, 956-62	16

251	Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients. 2014 , 70, 687-96	18
250	Predicting coronary heart disease in remote settings: a prospective, cross-sectional observational study. 2014 , 23, 737-42	
249	Effect of statin on the 5 years clinical outcomes in dialysis patients treated with sirolimus-eluting stent. 2014 , 53, 89-94	1
248	Neutrophil-to-lymphocyte ratio: an inflammation marker related to cardiovascular risk in children. 2015 , 114, 727-34	14
247	Association of Lipid Abnormalities with High-Sensitivity C - reactive Protein in Patients Treated with Atorvastatin. 2015 , 06,	
246	Effect of pretreatment of ezetimibe/simvastatin on arterial healing and endothelialization after drug-eluting stent implantation in a porcine coronary restenosis model. 2015 , 45, 110-6	2
245	What is the influence of hormone therapy on homocysteine and crp levels in postmenopausal women?. 2015 , 70, 107-13	9
244	Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity. 2015 , 56, 1519-30	115
243	Association of IL-6 and a functional polymorphism in the IL-6 gene with cardiovascular events in patients with CKD. 2015 , 10, 232-40	52
242	A brief elevation of serum amyloid A is sufficient to increase atherosclerosis. 2015 , 56, 286-93	57
241	Exercise and the Regulation of Inflammatory Responses. 2015 , 135, 337-54	58
240	Cardiovascular Biomarker Assessment Across Glycemic Status. 2015 , 245-268	0
239	The role of statins in inflammatory vasculitides. 2015 , 48, 177-80	17
238	Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial. 2015 , 58, 1494-502	23
237	Possible mechanisms of C-reactive protein mediated acute myocardial infarction. 2015 , 760, 72-80	27
236	High-Sensitivity C-Reactive Protein and Statin Initiation. 2015 , 66, 503-7	
235	Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. <i>Circulation</i> , 2015 , 132, 1224-33	16.7 189
234	Effect of vitamin D on bioavailability and lipid lowering efficacy of simvastatin. 2015 , 40, 87-94	6

233	Comprehensive Management of High Risk Cardiovascular Patients. 2016,	1
232	The relationship between serum levels of hs-CRP and coronary lesion severity. 2016, 89, 322-6	7
231	The Effects of Curcumin against the Inflammatory Response in Patients with Acute Coronary Syndrome. 2016, 5,	
230	Statins Dose-Dependently Exert Significant Chemopreventive Effects Against Various Cancers in Chronic Obstructive Pulmonary Disease Patients: A Population-Based Cohort Study. 2016, 7, 1892-1900	6
229	Atherogenesis and Inflammation. 2016, 1-16	
228	Impact of statin therapy on long-term clinical outcomes of vasospastic angina without significant stenosis: A propensity-score matched analysis. 2016, 223, 791-796	8
227	The Clinical Diagnosis and Management of Kawasaki Disease: a Review and Update. 2016, 18, 32	25
226	Hepatoprotective activity of ethanolic extract of Salix subserata against CCl4-induced chronic hepatotoxicity in rats. 2016, 16, 263	19
225	C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). 2016, 68, 873-881	21
224	Unmet needs in the management of atherosclerotic cardiovascular disease: Is there a role for emerging anti-inflammatory interventions?. 2016, 221, 581-6	11
223	Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance. 2016, 68, 1769-1780	59
222	Altered lipoproteins in patients with systemic lupus erythematosus are associated with augmented oxidative stress: a potential role in atherosclerosis. 2016, 18, 306	21
221	Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update. 2016, 128 Suppl 2, S216-28	4
220	Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. 2016, 37, 1720-2	114
219	A Test in Context: High-Sensitivity C-Reactive Protein. 2016, 67, 712-723	170
218	Mean platelet volume and cardiovascular outcomes in acute myocardial infarction. 2016, 8, 16-20	12
217	Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture. 2016, 80, 50-8	28
216	Effects of phytosterols on markers of inflammation: A systematic review and meta-analysis. 2016, 248, 76-83	63

215	Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases. 2016 , 37, 1799-806	65
214	Obesity and Cardiovascular Disease: a Risk Factor or a Risk Marker?. 2016 , 18, 21	143
213	Lipid Control and Beyond: Current and Future Indications for Statin Therapy in Stroke. 2016 , 18, 27	6
212	The association of albuminuria and high-sensitivity C-reactive protein with the efficacy of HMG-coenzyme A reductase inhibitors for cardiovascular event prevention. 2016 , 23, 847-55	
211	Proteomic analysis of HDL from inbred mouse strains implicates APOE associated with HDL in reduced cholesterol efflux capacity via the ABCA1 pathway. 2016 , 57, 246-57	36
210	From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. 2016 , 118, 145-56	462
209	Bone marrow mononuclear cells enhance anti-inflammatory effects of pravastatin against isoproterenol-induced myocardial infarction in rats. 2016 , 13, 393-402	3
208	Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need. 2016 , 21, 227-32	9
207	Meta-Analysis Comparing Rosuvastatin and Atorvastatin in Reducing Concentration of C-Reactive Protein in Patients With Hyperlipidemia. 2016 , 67, 526-35	8
206	Short-term changes on C-reactive protein (CRP) levels after non-surgical periodontal treatment in systemically healthy individuals. 2017 , 21, 477-484	17
205	Sex Differences in Inflammatory Markers and Health Status Among Young Adults With Acute Myocardial Infarction: Results From the VIRGO (Variation in Recovery: Role of Gender on Outcomes of Young Acute Myocardial Infarction Patients) Study. 2017 , 10, e003470	21
204	Association between Lp-PLA2 and coronary heart disease in Chinese patients. 2017 , 45, 159-169	16
203	High-sensitivity C-reactive protein is an independent marker of abnormal coronary vasoreactivity in patients with non-obstructive coronary artery disease. 2017 , 190, 1-11	16
202	Effects of atorvastatin treatment on left ventricular diastolic function in peritoneal dialysis patients-The ALEVENT clinical trial. 2017 , 11, 657-666	7
201	A dual-label time-resolved fluorescence immunoassay (TRFIA) for screening of Coronary atherosclerosis based on simultaneous detection of Lp-PLA and HsCRP. 2017 , 182, 12-17	5
200	Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. 2017 , 22, 1-26	31
199	High-sensitivity C-reactive protein levels and health status outcomes after myocardial infarction. 2017 , 266, 16-23	13
198	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. 2017 , 377, 1119-1131	3877

197	An Aggregate Biomarker Risk Score Predicts High Risk of Near-Term Myocardial Infarction and Death: Findings From BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes). 2017 , 6,	6
196	A Clinical Study of Lipid Abnormalities and Angiographic Profile in Patients of Coronary Artery Disease on Statins Undergoing Coronary Angiography. 2017 , 02, 011-018	
195	Preprocedural High-Sensitivity C-Reactive Protein Predicts Long-Term Outcome of Percutaneous Coronary Intervention. 2016 , 81, 90-95	20
194	Simvastatin reduces adrenal catecholamine secretion evoked by stimulation of cholinergic nicotinic and angiotensinergic AT receptors. 2018 , 41, 333-346	0
193	10-Year Resource Utilization and Costs for Cardiovascular Care. 2018 , 71, 1078-1089	22
192	Scoring system to predict early carotid restenosis after eversion endarterectomy by analysis of inflammatory markers. 2018 , 68, 118-127	9
191	Involvement of IL-1 β and IL-6 in antiarrhythmic properties of atorvastatin in ouabain-induced arrhythmia in rats. 2018 , 40, 256-261	2
190	Statins: pros and cons. 2018 , 150, 398-402	40
189	In vitro and in vivo delivery of atorvastatin: A comparative study of anti-inflammatory activity of atorvastatin loaded copolymeric micelles. 2018 , 32, 1127-1138	10
188	Prophylactic benefits of systemically delivered simvastatin treatment in a house dust mite challenged murine model of allergic asthma. 2018 , 175, 1004-1016	11
187	Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy. <i>Circulation</i> , 2018 , 138, 141-149	16.7 93
186	Inflammatory Mechanisms of Cardiovascular Remodeling. 2018 , 82, 629-635	53
185	A consensus statement on lipid management after acute coronary syndrome. 2018 , 7, 532-543	13
184	Will Reducing Inflammation Reduce Vascular Event Rates?. 2018 , 11, 317-319	7
183	Biomarkers in stable coronary artery disease. 2018 , 196, 82-96	23
182	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. 2018 , 391, 319-328	43 ⁰
181	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. 2018 , 12, 29-40	15
180	Role of Cholesterol as a Risk Factor in Cardiovascular Diseases. 2018 ,	3

179	Mechanisms and Treatments of Oxidative Stress in Atrial Fibrillation. 2018 , 24, 3062-3071		11
178	Diet-Modulated Lipoprotein Metabolism and Vascular Inflammation Evaluated by F-fluorodeoxyglucose Positron Emission Tomography. 2018 , 10,		1
177	Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention?. 2018 , 39, 4109-4111		16
176	Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. 2018 , 72, 3320-3331		81
175	Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome: JACC State-of-the-Art Review. 2018 , 72, 2886-2903		33
174	Wide-range CRP versus high-sensitivity CRP on Roche analyzers: focus on low-grade inflammation ranges and high-sensitivity cardiac troponin T levels. 2018 , 78, 346-351		6
173	Serum C-reactive protein in the prediction of cardiovascular diseases: Overview of the latest clinical studies and public health practice. 2018 , 233, 8508-8525		74
172	Atherosclerosis and inflammation: overview and updates. 2018 , 132, 1243-1252		317
171	Statins: pros and cons. 2018 , 150, 398-402		0
170	Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. 2018 , 50, 461-484		18
169	NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. 2018 , 122, 1722-1740		293
168	Critical roles of inflammation in atherosclerosis. <i>Journal of Cardiology</i> , 2019 , 73, 22-27	3	129
167	Clinical impact of high-sensitivity C-reactive protein during follow-up on long-term adverse clinical outcomes in patients with coronary artery disease treated with percutaneous coronary intervention. <i>Journal of Cardiology</i> , 2019 , 73, 45-50	3	7
166	PCSK9 inhibition and inflammation: A narrative review. 2019 , 288, 146-155		52
165	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. 2019 , 290, 140-205		259
164	Optical coherence tomography and C-reactive protein in risk stratification of acute coronary syndromes. 2019 , 286, 7-12		10
163	Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. 2019 , 124, 437-450		104
162	Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. 2019 , 115, 721-728		112

161	Sensors that Learn: The Evolution from Taste Fingerprints to Patterns of Early Disease Detection. 2019 , 10,	6
160	Nuclear Imaging: Focus on Vascular Probes. 2019 , 39, 1369-1378	6
159	Association of Plasma Levels of Nitric Oxide Oxidative Metabolites with Acute Stroke in Patients Presenting to the Emergency Department of a Low-Middle Income Country. 2019 , 2019, 9206948	1
158	High-sensitivity C-reactive protein and hypertension: combined effects on coronary severity and cardiovascular outcomes. 2019 , 42, 1783-1793	5
157	Growth Factors as Immunotherapeutic Targets in Cardiovascular Disease. 2019 , 39, 1275-1287	17
156	Statins: Rationale, Mode of Action, and Side Effects. 2019 , 171-200	3
155	Vitamin D3 supplementation ameliorates ovariectomy-induced cardiac apoptotic and structural changes in adult albino rats. 2019 , 97, 647-654	3
154	Von Mises Strain as a Risk Marker for Vulnerability of Carotid Plaque: Preliminary Clinical Evaluation of Cerebral Infarction. 2019 , 45, 1221-1233	4
153	A Control-Theoretic Model of Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2019 , 20, 6.3	7
152	C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial. 2019 , 210, 49-57	9
151	Inflammatory Markers and Novel Risk Factors. <i>Contemporary Cardiology</i> , 2019 , 87-98	0.1
150	Imaging inflammation in atherosclerotic plaques: Just make it easy!. 2019 , 26, 1705-1708	5
149	Association Between Systemic Inflammation, Carotid Arteriosclerosis, and Autonomic Dysfunction. 2020 , 11, 50-59	7
148	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. 2020 , 41, 111-188	2236
147	Controlling the thickness of the atherosclerotic plaque by statin medication. 2020 , 15, e0239953	3
146	Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. 2020 , 16, 361-379	36
145	Whole blood viscosity in microvascular angina and coronary artery disease: Significance and utility. 2020 , 39, 17-23	
144	Targeting cardiovascular inflammation: next steps in clinical translation. 2021 , 42, 113-131	63

143	Whole blood viscosity in microvascular angina and coronary artery disease: Significance and utility. 2020 , 39, 17-23	7
142	The effect of sour cherry consumption on blood pressure, IL-6, CRP, and TNF- α levels: A systematic review and meta-analysis of randomized controlled trials sour cherry consumption and blood pressure. 2020 , 32, 1687-1693	3
141	Dietary fiber of psyllium husk (<i>Plantago ovata</i>) as a potential antioxidant and hepatoprotective agent against CCl ₄ -induced hepatic damage in rats. 2020 , 130, 208-214	6
140	Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?. 2020 , 208, 107475	17
139	Residual Inflammation Indicated by High-Sensitivity C-Reactive Protein Predicts Worse Long-Term Clinical Outcomes in Japanese Patients after Percutaneous Coronary Intervention. 2020 , 9,	0
138	Combating Inflammation in Cardiovascular Disease. 2021 , 30, 197-206	13
137	Effect of compliance during periodontal maintenance therapy on c-reactive protein levels: a 6-year follow-up. 2021 , 48, 400-409	2
136	Optical Coherence Tomography Predictors for a Favorable Vascular Response to Statin Therapy. 2021 , 10, e018205	1
135	2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease.. 2021 , 23, 3	3
134	Effect of atorvastatin on lipogenic, inflammatory and thrombogenic markers in women with the metabolic syndrome. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 634-640	4.5 2
133	Statin Use Decreases the Risk of Metachronous Gastric Cancer in Patients without Infection. 2021 , 13,	1
132	Coronary heart disease risk: Low-density lipoprotein and beyond. 2021 ,	6
131	Enhancement the skin flap survival in mice applying topical and systemic atorvastatine:a randomized clinical trial study. 2021 , 2, 100049	0
130	Brief Report: Lower Socioeconomic Status Associates With Greater Systemic and Arterial Inflammation in HIV. 2021 , 87, 706-710	1
129	A phenome-wide association study of genetically mimicked statins. 2021 , 19, 151	1
128	Comparison of Transcriptomic Profiles of MiaPaCa-2 Pancreatic Cancer Cells Treated with Different Statins. 2021 , 26,	3
127	The role of systemic inflammation in heart failure. 2021 , 102, 510-517	
126	Short-Term and Lifelong Exercise Training Lowers Inflammatory Mediators in Older Men. 2021 , 12, 702248	0

125	Effect of smoking on culprit lesion plaque burden and composition in acute coronary syndrome: An intravascular ultrasound-virtual histology study. 2021 , 73, 687-692	
124	Lipids, Atherogenic Dyslipidemia, and Therapy. 347-408	1
123	Inflammation and Metabolic Syndrome. 210-228	4
122	Protection of endothelial function. 2005 , 619-44	11
121	Inflammation is a crucial feature of atherosclerosis and a potential target to reduce cardiovascular events. 2005 , 697-722	11
120	Lipids and atherosclerosis. 2004 , 791-807	2
119	Advances in lipid-lowering therapy in atherosclerosis. 2001 , 498, 49-58	8
118	Endothelial Dysfunction, Inflammation, and Exercise. 2009 , 131-147	1
117	Inflammation, C-Reactive Protein, and Vulnerable Plaques. 2007 , 611-620	2
116	A Primary Health-Care System Approach to Improving Quality of Care and Outcomes in People with Diabetes: The University of Pittsburgh Medical Center Experience. 2017 , 51-64	1
115	Homocysteine as a Risk Factor for Cerebrovascular Disease and Stroke. 2000 , 151-172	3
114	Lipids, Lipoproteins, Apolipoproteins, and Other Cardiovascular Risk Factors. 2012 , 731-805	4
113	Clinical approach to the inflammatory etiology of cardiovascular diseases. 2020 , 159, 104916	34
112	SAA-only HDL formed during the acute phase response in apoA-I ^{+/+} and apoA-I ^{-/-} mice. 1999 , 40, 1090-1103	46
111	Inflammation in Atherosclerosis-No Longer a Theory. 2021 , 67, 131-142	50
110	Evidence supporting secondary prevention strategies. 1999 , 14, 303-9	5
109	Novel risk factors for coronary heart disease: emerging connections. 2000 , 14, 91-103	6
108	Inflammation and infection in acute coronary syndrome. 2000 , 15, 13-26	8

107	Is cholesterol lowering with statins the gold standard for treating patients with cardiovascular risk and disease?. 2003 , 96, 220-2	6
106	C-reactive protein: the harbinger of cardiovascular diseases. 2008 , 101, 525-33	4
105	Multivessel myocardial infarction: a window to future treatments of myocardial infarction. 2010 , 2, 82-8	3
104	Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. 2017 , 127, 83-93	84
103	Systemic inflammatory response following acute myocardial infarction. 2015 , 12, 305-12	94
102	CMR plaque characterization. 2005 , 116-127	1
101	Early inflammatory markers are independent predictors of cardiac allograft vasculopathy in heart-transplant recipients. 2014 , 9, e113260	10
100	Value and level of plasma homocysteine in patients with angina pectoris undergoing coronary angiographic study. 2011 , 52, 280-5	4
99	Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients?. 2001 , 12, 814-821	90
98	Statins dose-dependently exert a significant chemopreventive effect on colon cancer in patients with chronic obstructive pulmonary disease: A population-based cohort study. 2016 , 7, 65270-65283	13
97	Ongoing clinical trials of the pleiotropic effects of statins. 2005 , 1, 29-40	35
96	Inflammation imaging to define vulnerable plaque or vulnerable patient. 2020 , 64, 21-34	2
95	The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?. 2011 , 12, 66-70	1
94	The changing spectrum of risk factors for coronary heart disease. 2009 , 51, 685-690	1
93	An elevated value of C-reactive protein is the only predictive factor of restenosis after percutaneous coronary intervention. 2003 , 18, 154-60	8
92	The Influencing Aspects of Atorvastatin on C-Reactive Protein and Lipid Profile in Patients with Stroke. 2008 , 3, 30-34	3
91	High sensitivity C-reactive protein (hsCRP) & cardiovascular disease: An Indian perspective. 2015 , 142, 261-8	62
90	Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome. 2015 , 6, 130-5	32

89	Effect of yoga training on inflammatory cytokines and C-reactive protein in employees of small-scale industries. 2017 , 6, 76		15
88	Residual Cardiovascular Risk: Inflammation the Primary Cause?. <i>World Journal of Cardiovascular Diseases</i> , 2018 , 08, 59-69	0	3
87	A Pediatric Opportunity in Adolescents to Prevent Adult Heart Attacks. <i>World Journal of Cardiovascular Diseases</i> , 2018 , 08, 85-101	0	2
86	The impact of in-stent neoatherosclerosis on long-term clinical outcomes: an observational study from the Kobe University Hospital optical coherence tomography registry. <i>EuroIntervention</i> , 2016 , 12, e1366-e1374	3.1	38
85	Pravastatin improves insulin resistance in dyslipidemic patients. <i>Journal of Atherosclerosis and Thrombosis</i> , 2005 , 12, 322-9	4	20
84	Assessment of serum leptin, pregnancy-associated plasma protein A and CRP levels as indicators of plaque vulnerability in patients with acute coronary syndrome. <i>Cardiovascular Journal of Africa</i> , 2012 , 23, 330-5	0.7	10
83	C-reactive Protein: A Prognostic Marker of Inflammation in Atherothrombosis. 2001 , 203-220		1
82	What about the statins?. <i>American Psychologist</i> , 2001 , 56, 365-366	9.5	1
81	Die koronare Herzerkrankung: Eine entzündliche oder infektiöse Krankheit?. 2001 , 99-109		
80	Clinical evidence of inflammation as a risk factor in ischemic stroke. 2001 , 13-26		
79	Coronary Atherosclerosis: Chronic Coronary Syndromes. 2002 , 779-820		
78	Pleiotropic effects of HMG-CoA reductase inhibitors on cells of the vascular wall. 2002 , 81-98		
77	Inflammation, Infection, and Homocysteine in Atherosclerosis. 2002 ,		
76	The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. 2003 , 45-50		1
75	Prognostic Role of Plasma High-Sensitivity C-Reactive Protein Levels in Acute Coronary Syndromes. 2003 , 291-303		
74	A biomarker of inflammation in cardiovascular disease. 2003 , 9-20		
73	C-Reactive Protein for Primary Risk Assessment. 2003 , 279-290		
72	The Scandinavian Simvastatin Survival Study (4S). 2003 , 96-109		

- 71 Gender and Its Impact on Risk Factors for Cardiovascular Disease. **2004**, 193-214 1
- 70 Risk Detection and Primary Prevention in Women. **2004**, 29-45
- 69 Bedside Platelet Monitoring. **2004**, 495-520
- 68 Treatment of Vulnerable Plaques. **2004**, 164-202
- 67 Vascular Inflammation as a Cardiovascular Risk Factor. **2005**, 577-604
- 66 Chronic infection and circulating markers of inflammation. **2005**, 448-465
- 65 The Relationship between Pulse Wave Velocity and Serum Inflammatory Markers among Healthy Adults in a Community. *Kitakanto Medical Journal*, **2006**, 56, 201-206 0
- 64 Analytic Issues for Clinical Use of C-Reactive Protein. **2006**, 223-235
- 63 Inflammatory Mediators and C-Reactive Protein. *Fundamental and Clinical Cardiology*, **2006**, 441-462
- 62 Type 2 Diabetes. *Fundamental and Clinical Cardiology*, **2006**, 187-254
- 61 1. ??????????????. *Japanese Journal of Clinical Pharmacology and Therapeutics*, **2007**, 38, 295-298 0
- 60 Biomarkers of Inflammation as Surrogate Markers in Detection of Vulnerable Plaques and Vulnerable Patients. **2007**, 641-651 1
- 59 Risk Factors for Cardiovascular Disease and Arterial Thrombosis. **2007**, 371-378
- 58 Obesity and Inflammation. *Oxidative Stress and Disease*, **2007**, 139-165
- 57 The Potential Role of Statins in Severe Sepsis. **2008**, 19-28
- 56 Modulation of Biomarkers of Inflammation. **2009**, 396-409
- 55 The Link Between Inflammation and Thrombosis. **2010**, 39-61
- 54 Early Initiation of Statin Treatment Immediately after Acute Myocardial Infarction Improves Clinical Outcomes. *Chonnam Medical Journal*, **2010**, 46, 25

- 53 Inflammatory Markers and Novel Risk Factors. **2011**, 107-123
- 52 Advanced Lipid Testing. **2011**, 77-103
- 51 Biomarkers in Acute Ischemic Heart Disease. **2011**, 101-112
- 50 Novel biomarkers in evaluation of acute coronary syndrome. **2011**, 131-138
- 49 Collagen Vascular and Infectious Diseases. **2011**, 687-702
- 48 Atherogenesis and Inflammation. 10-29
- 47 Cardiac Function. **2012**, 1457-1522 1
- 46 Integration of Biomarkers with Plaque Imaging. *Contemporary Cardiology*, **2014**, 203-214 0.1
- 45 Statin therapy for elderly patients should be assessed for each individual. **2016**, 2,
- 44 Behavior of Ultrasensitive C-Reactive Protein in Myocardial Revascularization with and without Cardiopulmonary Bypass. *Brazilian Journal of Cardiovascular Surgery*, **2018**, 33, 535-541 1.1
- 43 In Defense of the LDL Hypothesis. *World Journal of Cardiovascular Diseases*, **2019**, 09, 245-252 0
- 42 Secondary prevention after acute coronary syndrome. *Vnitřní Lekarství*, **2020**, 66, 236-241 0.3
- 41 C-reactive protein and cardiovascular disease: From animal studies to the clinic (Review). *Experimental and Therapeutic Medicine*, **2020**, 20, 1211-1219 2.1 3
- 40 C-Reactive Protein and Other Inflammatory Markers in Cardiovascular Disease: Inflammatory Disorders and Atherosclerosis. *Contemporary Cardiology*, **2021**, 565-583 0.1 1
- 39 Lipide. **2005**, 362-377
- 38 Stable Angina. **2005**, 451-470
- 37 Inflammation and Infection in Coronary Artery Disease. **2006**, 29-45
- 36 Vascular Dysfunction in Short-Term Hypercholesterolemia despite the Absence of Atherosclerotic Lesions. *Journal of Cardiovascular and Thoracic Research*, **2011**, 3, 73-7 1.3 3

35	Effect of cardiac rehabilitation on inflammation: A systematic review and meta-analysis of controlled clinical trials. <i>ARYA Atherosclerosis</i> , 2018 , 14, 85-94	0.7	3
34	Relationship of C-reactive protein, metabolic syndrome and diabetes mellitus: potential role of statins. <i>Journal of the National Medical Association</i> , 2005 , 97, 1600-7	2.3	8
33	PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. <i>Texas Heart Institute Journal</i> , 2009 , 36, 530-9	0.8	9
32	C-Reactive Protein: How Has JUPITER Impacted Clinical Practice?. <i>Ochsner Journal</i> , 2009 , 9, 204-10	1.5	6
31	Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?. <i>Transactions of the American Clinical and Climatological Association</i> , 2013 , 124, 174-90	0.9	56
30	Cardiovascular events and safety outcomes associated with azithromycin therapy: a meta-analysis of randomized controlled trials. <i>American Health and Drug Benefits</i> , 2014 , 7, 318-28	1.7	24
29	Significant reduction in the LDL cholesterol increases the risk of intracerebral hemorrhage: a systematic review and meta-analysis of 33 randomized controlled trials. <i>American Journal of Translational Research (discontinued)</i> , 2020 , 12, 463-477	3	6
28	Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis.. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 ,	4.5	1
27	Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021 , 20, 220	8.7	5
26	Combined impact of residual inflammatory risk and chronic kidney disease on long-term clinical outcomes in patients undergoing percutaneous coronary intervention. <i>Journal of Cardiology</i> , 2021 ,	3	0
25	Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	0
24	Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. <i>Mediators of Inflammation</i> , 2022 , 2022, 8732360	4.3	4
23	Cardiac biomarkers: definition, detection, diagnostic use, and efficiency. 2022 , 113-130		
22	Metabolic Syndrome: Updates on Pathophysiology and Management in 2021.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	24
21	Inflammation as a mechanism and therapeutic target in peripheral artery disease.. <i>Canadian Journal of Cardiology</i> , 2022 ,	3.8	0
20	The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. <i>Molecular and Cellular Biochemistry</i> , 2003 , 246, 45-50	4.2	11
19	Periodontal Disease Association with Large-Artery Atherosclerotic Stroke.. 2021 , 8,		
18	Atherogenesis and Inflammation. 2022 , 1-20		

17	Biomarkers of cardiovascular diseases. 2013 , 47, 11-19		
16	High-Sensitivity C-Reactive Protein. <i>Contemporary Cardiology</i> , 2022 , 347-375	0.1	
15	Commercial Hormone Replacement Therapy Jeopardized Proinflammatory Factors in Experimental Rat Models. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022 , 10, 977-981	1	
14	The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis. <i>Frontiers in Cardiovascular Medicine</i> , 9,	5.4	
13	Plaque characteristics and biomarkers predicting regression and progression of carotid atherosclerosis. <i>Cell Reports Medicine</i> , 2022 , 3, 100676	18	o
12	Local simvastatin and inflammation during periodontal mini-flap wound healing: Exploratory results.		
11	Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome. 9,		o
10	Inflammation in coronary artery disease-clinical implications of novel HDL-cholesterol-related inflammatory parameters as predictors. Publish Ahead of Print,		1
9	Serum amyloid A1 and pregnancy zone protein in pregnancy complications and correlation with markers of placental dysfunction. 2022 , 100794		o
8	Rationale and design of COLchicine On-admission to Reduce inflammation in Acute Coronary Syndrome (COLOR-ACS) study. Publish Ahead of Print,		o
7	Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome. 9,		o
6	Post-PCI Risk Assessment by Inflammation Activity According to Disease Acuity and Time from Procedure.		o
5	Multifaceted role of cardiovascular biomarkers. 2023 , 75, 91-97		o
4	The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review. 2023 , 2, 122-164		o
3	Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials. 2023 , 373, 1-9		o
2	Revascularization and Medical Therapy for Chronic Coronary Syndromes: Lessons Learnt from Recent Trials, a Literature Review. 2023 , 12, 2833		o
1	Understanding the molecular mechanisms of statin pleiotropic effects.		o